1. Introduction {#s0005}
===============

There are currently about 132 therapeutic agents in 156 clinical trials for Alzheimer\'s disease (AD) ([@bb0380]). Among these are about 29 disease-modifying monoclonal antibody therapies involved in 24 clinical trials ([@bb0375], [@bb0380]), nearly all of which target two key proteins recognized as the major hallmarks in AD pathology: A*β* and tau protein. In AD pathology, A*β* forms extracellular plaques as well as oligomers that can spread the disease by propagating from cell-to-cell. Tau forms neurofibrillary tangles in neurons, and can also form oligomers that spread pathology by propagating from cell-to-cell. This review will focus on therapies targeting A*β* and tau in clinical trials, related therapies in pre-clinical development, and the underlying biochemical mechanisms that motivate researchers to hypothesize that these therapies will be effective in treating AD.

In describing the common mechanisms that underly the effectiveness of potential antibody therapeutics, we found ourselves emphasizing general themes of antibody development that various different therapeutic strategies may have in common. As well, A*β* and tau have been shown to have intimately connected pathology, and therapeutic strategies targeting A*β* exclusively have had a long history fraught with ambiguous results and minimal therapeutic benefit. For these reasons it became almost inevitable to include both A*β* and tau therapies in the same review. As some examples of biochemical similarity, both A*β* and tau have both been shown to have distinct, pathological species with conformations different from the healthy proteins, both are subject to isoform imbalance as a cause or symptom of pathology, both undergo post-translational modifications specific to pathological behavior that have been targeted by several candidate therapeutics, and both have been shown to form oligomers that propagate from cell-to-cell in prion-like fashion, which constitute therapeutic targets of specific interest.

Several excellent recent articles have reviewed current clinical developments for A*β* immunotherapies ([@bb1015]; [@bb0950]; [@bb0915]; [@bb1515]; [@bb1105]), tau immunotherapies ([@bb1125]; [@bb1365]; [@bb1065]; [@bb1350]; [@bb0970]; [@bb0725]; [@bb0700]), or both A*β* and tau immunotherapies ([@bb0300]; [@bb1190]; [@bb1100]; [@bb1645]; [@bb0715]; [@bb0445]; [@bb0375]; [@bb0820]; [@bb0960]). The widely read Alzforum domain ([www.alzforum.org](http://www.alzforum.org){#ir0365}) is another useful source of both current and archival clinical and pre-clinical results. Our approach here has been to try to emphasize the conceptual bases underlying the strategies for the development of various immunotherapies. For example, we discuss the custom immunogens used in the active immunization phase, why they were chosen, and how they may lead to disease-selective antibodies. We also sought to describe the rationale for targeting specific epitopes, including those that appear to have disease-selective post-translational modification. The task of epitope prediction, in order maximize the efficacy of a therapeutic, is a difficult one that is understandably under-addressed. We briefly discuss a method for misfolding-specific epitope prediction ([@bb1130]) here. We also discuss in detail the notions of conformational-plasticity of the target proteins A*β* and tau, and the conformational-selectivity in binding profile that an effective antibody therapeutic should possess.

1.1. Rationale for targeting A*β* and tau {#s0010}
-----------------------------------------

There is now an enormous amount of independently gathered genetic, neuropathological, and experimental data supporting the connection between A*β* aggregation and the cognitive symptoms of AD, collectively referred to as the amyloid cascade hypothesis ([@bb0645]; [@bb0650]; [@bb0640]; [@bb0815]; [@bb1325]; [@bb1645]). Overexpresssion of A*β* due to trisomy 21 in individuals with Down syndrome associates with early-onset AD ([@bb0165]; [@bb0655]). Over 30 mutations in amyloid precursor protein, in and around the region of the A*β* peptide, are associated with inherited forms of AD ([@bb1510]; [@bb0085]). The mutation A673T in APP, which reduces amyloidogenic BACE1 processing of APP and to a lesser extent decreases A*β* ~42~ peptide aggregation, is protective against AD ([@bb0785]; [@bb0940]). *γ*-secretase processively cleaves APP to make A*β* peptides of appropriate length; this is dependent on the stability of its catalytic presenilin-1 (PSEN1) transmembrane domain.

Over 350 mutations in the intramembrane protease *γ*-secretase, more than 300 of which are in the presenilin-1 (PSEN1) domain,[1](#fn0005){ref-type="fn"} increase the production of amyloidogenic A*β* ~42~ and cause some of the earliest, most aggressive forms of familial AD ([@bb1290]; [@bb0415]). The PSEN2 domain of *γ*-secretase, which shares 67% homology to PSEN1, also contains about 38 currently known AD-associated mutations^1^. PSEN2 plays a secondary role to PSEN1 in AD, and many mutations of PSEN2 are not fully penetrant ([@bb0245]). Dominantly inherited AD is thus caused by mutations in either the substrate or protease enzyme in the reaction that produces A*β*. A significant correlation between the thermal stability of the PSEN1--A*β*n complex, as determined by melting temperatures (*T* ~*m*~) of various AD-linked PSEN1 mutants, and the initial age of onset of AD has been observed ([@bb1440]). This effect is hypothesized to be due to increased dissociation rates of the complex, resulting in reduced processivity, and thus the release of longer, incompletely processed A*β* peptides.

Apolipoprotein E (APOE) is a protein involved in the metabolism of fats in the body and is the principal cholesterol carrier in the brain ([@bb1185]). APOE exists in three main polymorphisms among the human population differing by two amino acid identities: namely the *ε*2 (C112, C158), *ε*3 (C112, R158), and *ε*4 (R112, R158) isoforms. The *ε*3 isoform is the most common (78% worldwide allele frequency). Individuals carrying APOE *ε*2/*ε*2 or *ε*2/*ε*3 (8.4% of the population) are at decreased risk of AD ([@bb0910]). In vitro and in vivo evidence in APP transgenic mice has shown that APOE-*ε*3, but not APOE-*ε*4, attenuates A*β* protofibril-induced aggregation, by forming stabilizing complexes with A*β* ([@bb0695]). As well, the APOE-*ε*4 isoform is not as effective as the others at clearing A*β* ([@bb0770]; [@bb0270]), and carriers of two copies of the *ε*4 allele have on average 20× the risk of developing AD ([@bb0660]). The *ε*4 variant of APOE is currently the most significant known genetic risk factor for late-onset sporadic AD ([@bb1260]; [@bb1255]).

Normally functioning TREM2, which encodes triggering receptor expressed on myeloid cells 2, facilitates microglia activation and clustering around amyloid and neurofibrillary tangles, increasing amyloid uptake, phagocytic activity, and plaque compaction in early stages of AD ([@bb0405]; [@bb0670]). These processes are impaired in AD-associated variants of TREM2, resulting in filamentous plaques associated with increased dystrophic neurites and a possible increase of tau pathology. ([@bb0765]; [@bb1500]; [@bb0565]; [@bb1695]). Some variants of the TREM2 gene have been found to cause increased susceptibility to late onset AD with an odds ratio similar to that of ApoE-*ε*4 ([@bb0595]; [@bb0790]). The TREM2 mutant with the strongest AD association, R47H, has 3--4× the AD risk as wild-type, and shows significantly reduced A*β* -induced microglial responses in transgenic mouse models. Since TREM2 is exclusively expressed on immune cells, the above findings provide a direct link between dysregulation of the innate immune system as an active driver contributing to AD pathogenesis.

In summary, abundant evidence points to the progressive accumulation of A*β* in the brain, along with its impaired clearance and induced neuroinflammation, as very early features of the Alzheimer\'s pathogenic process.

More recent findings from genome-wide association studies (GWAS) and massive parallel resequencing (MPS) efforts emphasize the multifactorial nature of AD. There are currently over 25 genetic risk loci that contribute to the 60--80% heritability estimate for one\'s genetic predisposition for AD ([@bb1510]). Risk-associated genes roughly cluster into 3 biochemical pathways: cholesterol and lipid metabolism, immune system and inflammatory response, and endosomal vesicle cycling.

Early biomarkers of AD precede any clinically discernable changes in cognition by many years, perhaps decades ([@bb1540]). The first known biomarker is decreased CSF A*β* ~42~, followed by increased brain A*β* amyloid load; This is then followed by increased concentration of CSF tau (both total and phosphorylated), then decreased glucose metabolism as measured by fluorodeoxyglucose PET ([@bb0720]; [@bb0735], [@bb0740]). It is now accepted that accumulation of tau correlates more closely with severity of dementia than does amyloid load ([@bb1475]; [@bb0110]; [@bb0170]; [@bb1030]; [@bb1340]; [@bb1035]), however there is now evidence that A*β* accumulation can exacerbate tau misfolding and pathology, and vice versa ([@bb0795]; [@bb0115]; [@bb0400]; [@bb1210]).

2. Immunization strategies; active immunization {#s0015}
===============================================

Allmost all antibody therapies require some form of active immunization strategy for their generation. The immunization strategy is often a critical step in the development pipeline, as it largely determines the binding profile and selectivity of the resulting antibody.

2.1. Lessons learned from active immunization {#s0020}
---------------------------------------------

The very first forays into antibody therapy were a form of active immunization involving inoculation with a less virulent form of the small pox virus, in the 1700\'s by early medical practitioners such as Benjamin Jesty and Edward Jenner ([@bb1245]). Historically, active immunization has been used to prevent the spread of infectious diseases, before infection has occurred, while passive immunization has been used after symptoms have already manifest ([@bb0045]). It may be interesting and potentially fruitful to revisit this paradigm in treating AD at its various stages, either as treatment or for prophylaxis. However, in cancer, where roughly 30 passive immunotherapies are currently available and 30 more are in late stage clinical trials ([@bb0255]; [@bb0045]; [@bb0810]), only two active vaccines have been approved as therapies ([@bb0575]).

Several other active immunizations are currently in clinical trials, including CAD106 (phase III, [NCT02565511](NCT02565511){#ir0380}), UB-311 (phase II, [NCT03531710](NCT03531710){#ir0385}), and GV1001 (phase II, [NCT03959553](NCT03959553){#ir0390}) for A*β* ([@bb1630]; [clinicaltrials.gov](http://clinicaltrials.gov){#ir0395}).

Active vaccination trials raise an interesting possibility to obtain human A*β* or tau antibodies from B-cell pools isolated from the best responders, for subsequent use as effective passive immunotherapeutics. Thus far however, there appears to be no published work seriously pursuing this possibility, albeit selection of effective clones involves significant technical challenges. Similar lines of development have been pursued for aducanumab and BIIB076, described in more detail below.

### 2.1.1. Active A*β* immunotherapy: AN1792 {#s0025}

The first active immunization trials using the AN1792 vaccine, which consisted of fibrillar A*β* ~42~ as the immunogen as well as the QS21 adjuvant, had to be halted because approximately 6% (18/298) of the volunteers developed symptoms of aseptic meningoencephalitis (infiltration of T cells and macrophages) ([@bb0530]). Nevertheless, several important lessons were learned from these trials. First, the efficacy of the vaccine in removing A*β* load was validated: There was a dramatic clearance of plaques in the brain parenchyma of the volunteers, with broad areas of cerebral cortex devoid of plaques. Some of these patients have remained virtually plaque-free for 14 years, with the extent of plaque removal related to the degree of immune response ([@bb1045]). Vascular amyloid and tau-related pathology were not targeted: Tau-reactive neurofibrillary tangles (NFTs) persisted, as well as amyloid in cerebral vessels. CSF tau was decreased in antibody responders however. The immune response in these cases appears to work as a double-edged sword: Anti-A*β*-specific T cells could induce significant adverse effects in AD patients vaccinated with full-length A*β* ~42~. Cognitive benefits were observed in a neuropsychological test battery (NTB), favoring responders versus placebo, with greater improvements from baseline associated with higher IgG antibody titers in the responders. However, other cognitive tests such as ADAS--Cog, Disability Assessment for Dementia (DAD), Clinical Dementia Rating (CDR), and MMSE showed no significant differences. After 4.6 years, the patients in this study were re-tested using the above metrics. Antibody responders demonstrated a 25.0% lower decline in daily activities as determined by the DAD, a 17.6% lower mean score in caregiver dependence, and a 20.2% less decline on the CDR scale compared with placebo-treated patients ([@bb1525]). However, no significant differences were observed in the NTB, MMSE, ADAS-Cog tests. On the other hand, in the post-mortem follow-up over a 15-year period, all patients progressed from mild/moderate dementia to moderate/severe dementia; Notably, all five patients with near complete clearance of brain plaques progressed to severe dementia prior to death. These results from the AN1792 trial---though mixed---suggest that A*β* immunotherapy, passive or active, could be helpful in current and future human trials, provided the targeting and time of application are appropriate. On the other hand, the generic targeting of A*β* that is induced from active immunization may not be sufficiently specific to result in long term cognitive benefit across multiple metrics. The observed sustained amyloid clearance over many years implies that if A*β* immunotherapy is useful as a *preventative* rather than a treatment, then early active immunization could in fact be an effective strategy. That is, sustained constitutive removal of all forms of A*β* (monomer, oligomer, and plaque), before it has a chance to accumulate and propagate, may be an effective strategy for treatment of AD.

### 2.1.2. Active tau immunotherapy: AADvac-1 and ACI-35 {#s0030}

As described in more detail below in the context of tau passive immunotherapies (see Preclinical tau antibodies), mice actively immunized with tau peptides containing the HXPGGG motif generated antibodies that could block the oligomerization of tau. This approach seeks to generate antibodies that block aberrant tau--tau interactions, rather than those selective to pathological phosphorylation sites. A complementary strategy to mouse active immunization, and subsequent humanization for a passive immunotherapy, is to directly immunize humans with a similar peptide. AADvac-1 utilizes a peptide containing one of the epitopes of antibody DC8E8 (see Setion 5.10), namely ^294^KDNIKHVPGGGS^305^, conjugated to keyhole limpet hemocyanin (KLH) along with aluminum hydroxide as an adjuvant.

In phase I trials testing the immunogenicity and safety of the vaccine in patients with mild-to-moderate AD ([NCT01850238](NCT01850238){#ir0400}), AADvac-1 was found to be well-tolerated: The vaccine elicited no aberrant immune response or microhemorrhages compared to what was observed with AN1792 ([@bb1060], [@bb1075]). Minor injection site reactions were the most common adverse event, observed in 53% participants. In a follow-up study 72 weeks after conclusion ([NCT02031198](NCT02031198){#ir0405}) involving 26 of the same participants, no aberrant immune responses were reported, except for microhemorrhages in one patient. Interestingly, cognitive decline as measured by baseline ADAS-cog11 value was shown to be significantly reduced in treated patients compared with placebo control ([@bb1070]). These results have prompted AADvac-1 to move into a phase II clinical trial ([NCT02579252](NCT02579252){#ir0410}) whose preliminary results have very recently been reported ([@bb0125]). The vaccine was again deemed safe and tolerable. Roughly 98% of patients generated antibodies against tau. Neurofilament Light Chain (NfL) biomarkers indicated significant slowing of neurodegenerative progression. AD-specific CSF pathological tau biomarkers, including phospho-tau181 and phospho-tau217, also appeared to show moderate to large reductions. Among the younger participants in the trial, there appeared to be positive signals for cognitive endpoints according to CDR-SB, MMSE, and ADCS-MCI-ADL tests, however the strength and significance has not yet been reported.

ACI-35 utilizes a liposomal-anchored 16-amino acid tetra-palmitoylated phospho-tau peptide, ^393^VYKSPVVSGDTSPRHL^408^, with S396 and S404 phosphorylated, as they can be in pathological tau. The liposome sizes are such that they can accommodate ≈16 copies of the peptide. Presenting tau on liposomes alters the epitope conformation: Circular dichroism (CD) shows a significant amount of *β*-sheet structure on the liposome surface similar to that of aggregated tau ([@bb1470]).

In tau-transgenic mouse models, ACI-35 decreased both soluble and insoluble tau, increased retention of body weight, slightly extended lifespan, and improved the clinical phenotype of motor deficiency ([@bb1140]; [@bb1470]). The vaccine also did not induce marked CNS inflammation in spite of presenting multiple (16) copies of the epitope ([@bb1470]).

3. Immunization strategies; rational engineering of antibodies and antibody design {#s0035}
==================================================================================

In guiding species selectivity and thus the efficacy of an antibody, the immunization strategy is central in determining which sub-population of the conformational ensemble of an epitope that an antibody will bind to. Guiding the epitope towards a desired conformational sub-population is often referred to as "epitope scaffolding" (see e.g. [@bb1385]; [@bb1080]; [@bb0345]; [@bb0140]). A rational approach to immunization can save much effort by avoiding the subsequent high-throughput screens that are necessary when immunizing irrationally with generic polymorphic forms of a protein.

3.1. Advantages of using antibody-based therapies to target A*β* and tau {#s0040}
------------------------------------------------------------------------

The protein drug targets A*β* and tau are both largely intrinsically disordered peptides when isolated as monomers in solution, and as such they are conformationally labile. Such polymorphic targets are inherently difficult to target for small-molecules, which are best-adapted to fit into well-structured binding pockets ([@bb1315]). On the other hand, antibodies are well suited to bind to disordered peptide segments. The selective binding of antibodies to regions of proteins that become disordered during the course of disease has been exploited to generate misfolding-specific antibodies for several proteins wherein misfolding is correlated with neurodegeneration ([@bb1115]; [@bb0535]; [@bb1220]; [@bb0225]; [@bb0135]).

3.2. Epitope prediction {#s0045}
-----------------------

In choosing the appropriate protein sequence and conformation for active immunization, ideally one would employ a reliable method for epitope prediction, and then use an immunogen appropriately displaying that epitope as it presents in toxic species. This is an enormous challenge at present: Our understanding of what proteinic features can be ubiquitously targeted on toxic species that are involved in the spread of AD is limited at present. Soluble oligomeric species that are thought to be central to the prion-like propagation of AD are conformationally plastic---they do not have a well-defined structure that would lend themselves to structural determination and subsequently epitope identification.

As described further in the examples below, epitopes are either left unidentified when immunizations with pathogenic species such as fibrils or oligomers are used, or a disease-specific isoform is used in the immunogen (e.g. A*β* ~42~ rather than A*β* ~40~), or a known post-translational modification observed in pathogenic species is incorporated onto a peptide fragment presented on the immunogen (e.g. phosphorylation of a serine residue, or pyroglutamate cyclization of a glutamic acid).

One method of epitope prediction used for the design of antibodies targeting tau and A*β* involves computational prediction of regions likely to be selectively exposed on the surface of soluble oligomers. This molecular dynamics approach applies the concept of a misfolding-specific epitope, useful in the context of other neurodegenerative diseases ([@bb1115]; [@bb1220]; [@bb1130]), to the problem of finding epitopes for A*β* and tau. In brief, a fibril structural model is weakened and disrupted by applying a global force along a collective coordinate. The weakest parts of the fibril complex are the first to become disordered, and constitute "stressed protofibril"-specific epitopes ([@bb1145]).

3.3. Epitope scaffolding for conformationally selective antibodies {#s0050}
------------------------------------------------------------------

We first describe an experiment providing strong evidence that Alzheimer\'s disease is a "conformational" disease of A*β*, which emphasizes the importance of conformation in the active immunization stage of antibody development. Peptides of A*β* ~1−15~ or A*β* ~1−16~ may be tethered to a liposome surface by conjugating two palmitoylated lysine residues at either end of the peptide, so that, for example the sequence of A*β* ~1−16~ is K*~pal~* K*~pal~* DAE...HQKK~*pal*~ K~*pal*~ ([@bb1040]). Additionally, the termini of the peptide may be PEGylated to provide an additional 77 units of spacing between the peptides and the liposome. [@bb1025] found, by CD and NMR measurements, that PEGylated, liposome-anchored A*β* preferred a random coil conformation, while non-PEGylated, liposome anchored A*β* preferred a *β*-sheet conformation, apparently due to enhanced proximity of the peptide to the liposome surface.

Importantly, inoculation of APP/PS-1 double-transgenic mice with liposome anchored A*β* elicited an IgG immune response that resulted in restoration of memory deficits, while inoculation with PEGylated, liposome-anchored A*β* elicited an IgM immune response with no memory benefits ([@bb1025]). This experiment indicates that antigens presenting N-terminal epitopes of A*β* in what is likely a *β*-sheet-like conformation will elicit antibodies that target pathogenic, memory-reducing, species of A*β*. These liposomal compounds have been developed as an active vaccine (ACI-24) and are currently in phase 1/2 clinical trials ([NCT02738450](NCT02738450){#ir0415}) in adults with Down syndrome. The pre-humanized murine antibody (mMABT) to crenezumab was generated by liposome-anchored A*β* inoculation, using an epitope subsuming residues 13--24.

3.4. Conformational selectivity {#s0055}
-------------------------------

Because of the above-mentioned disorder present in A*β* and tau, these proteins can present themselves to an antibody in multiple different conformations. It is often desirable for an antibody to be conformationally selective to a specific species ([@bb1620]). For example, soluble A*β* is present in normal patient brains at a concentration of about a picomolar, while in AD brains it is present at concentrations \~0.1nM ([@bb0930]). Oligomer concentrations are less well-known but are thought to be about a 1000-fold lower in concentration ([@bb1680]). An antibody that is not conformationally selective for oligomer would suffer from target distraction by binding to the much more abundant monomer species, and thus lack sufficient target engagement.

The brains of healthy (non-AD presenting) elderly patients may contain insoluble A*β* amyloid plaque at concentrations comparable to AD patients ([@bb0930]); Diffuse senile plaques in the cerebral cortex have been considered to be age-related and unassociated with dementia (see e.g. [@bb1445]). Thus, antibodies that bind generically to plaque may again suffer from target distraction, as well as additional clinical risks, particularly for antibodies binding to vascular deposits. In these cases, monocytes and other lymphocytes are recruited to clear the amyloid, and binding of antibody complexes to Fc receptors on macrophage-like cells stimulates the expression of proteases, which in turn degrade the extracellular matrix at those locations. Blood-brain barriers at the vessel wall are thus weakened, insterstitial fluid can enter the brain, and microhemorrhaging can occur ([@bb1295]). This leakiness of brain vasculature manifests itself through amyloid-related imaging abnormalities (ARIA), which as mentioned above is generally accompanied by microhemorrhaging (ARIA-H) and/or edema (ARIA-E) (see [Table 1](#t0005){ref-type="table"} for ARIA levels for various A*β* immunotherapies).Table 1Antibodies to A*β* currently in clinical development.Table 1AntibodyEpitope locationImmunization strategyBinding Selectivity[b](#tf0010){ref-type="table-fn"}Ab species and backbone isotypeCurrent Status (2019-2020)CompanyClinical outcomesLast completed Trial (Phase)Patient stageReduced brain Ab burdenSlowing of cognitive declineARIA-E or ARIA-HBapineuzumab (AAB-001, 3D6)1--5A*β* (1--5) conjugated to immunoglobulinM,O,F/PHumanized IgG1[NCT00998764](NCT00998764){#ir0045}, [NCT00667810](NCT00667810){#ir0050}, [NCT00996918](NCT00996918){#ir0055} (III,D)Janssen/Pfizer[NCT00575055](NCT00575055){#ir0060}, [NCT00574132](NCT00574132){#ir0065} (III)Mild to moderate AD+−highSolanezumab (LY2062430, m266)16--26A*β* peptide 13--28M++,O,F/P-Humanized IgG1[NCT01900665](NCT01900665){#ir0070} (III,halted), [NCT02008357](NCT02008357){#ir0075} (III)Eli Lilly[NCT00904683](NCT00904683){#ir0080}, [NCT00905372](NCT00905372){#ir0085} (III)Mild to moderate AD++/−[c](#tf0015){ref-type="table-fn"}noPonezumab (PF-04360365)30--40A*β*~40~M+,O,F (A*β*~40~)Humanized IgG2a[a](#tf0005){ref-type="table-fn"}[NCT00945672](NCT00945672){#ir0090} (II,D)Janssen/Pfizer[NCT00722046](NCT00722046){#ir0095} (II)Mild to moderate AD−−low ARIA-H, low ARIA-ECrenezumab (MABT5102A, RG7412)13--24liposome-anchored peptidesM-,O, F/PHumanized IgG4[NCT02670083](NCT02670083){#ir0100} (III,D), [NCT01998841](NCT01998841){#ir0105} (II)Roche/Genentech[NCT01723826](NCT01723826){#ir0110} (II)Mild to moderate AD−−lowGantenerumab (RO4909832, RG1450)2--11 and 18--27N/A: human combinatorial antibody librariesM-, O, F/P+human IgG1[NCT03443973](NCT03443973){#ir0115}, [NCT03444870](NCT03444870){#ir0120} (III)Hoffman-La Roche[NCT01224106](NCT01224106){#ir0125}, [NCT02051608](NCT02051608){#ir0130} (III)Prodromal to mild AD+−high: 2/6 patients (200 mg dose)Donanemab (N3pG, LY-3002813, mE8)p3--7A*β* pE3--42 peptideF/P (N3pG)Humanized IgG1[NCT02624778](NCT02624778){#ir0135} (I), [NCT03367403](NCT03367403){#ir0140} (II)Eli Lilly[NCT01837641](NCT01837641){#ir0145} (I)Early/mild AD+n/amoderate; immunogenicAducanumab (BIIB037)3--7N/A: B-cell libraries from healthy elderly subjectsM-,O,F/PHuman IgG1[NCT02477800](NCT02477800){#ir0150}, [NCT02484547](NCT02484547){#ir0155} (III, D)Neurimmune/Eisai/Biogen[NCT02477800](NCT02477800){#ir0160}, [NCT02484547](NCT02484547){#ir0165} (III)Early AD+−highSAR-228810 (SAR255952, 13C3)N-terminus (4--20)Synthetic oligomersO,F/PHumanized IgG4[a](#tf0005){ref-type="table-fn"}[NCT01485302](NCT01485302){#ir0170} (I)Sanofi[NCT01485302](NCT01485302){#ir0175} (I)Mild to moderate ADn/an/ano ARIA-E, very low ARIA-HBAN-2401 (Lecanemab, mAb158)N-terminus (1--16)Protofibrils of E22G mutant A*β*M-,O+, F/PHumanized IgG1[NCT03887455](NCT03887455){#ir0180} (III)Biogen/Eisai/BioArctic[NCT01230853](NCT01230853){#ir0185} (I), (Iib)Mild to moderate AD/Early AD++/−lowMEDI-1814A*β*~42~ C-terminus (29--42)N/A: human combinatorial antibody librariesM++,OHuman IgG1[a](#tf0005){ref-type="table-fn"}[NCT02036645](NCT02036645){#ir0190} (I)Eli Lilly/AstraZeneca/MedImmune[NCT02036645](NCT02036645){#ir0195} (I)Mild to moderate ADn/an/anoKHK6640Not known/Not disclosedNot availableO,F/PHumanized IgG4[a](#tf0005){ref-type="table-fn"}[NCT03093519](NCT03093519){#ir0200} (I)Kyowa Hakko Kirin[NCT02127476](NCT02127476){#ir0205} (I), [NCT03093519](NCT03093519){#ir0210} (I)Prodromal/Mild/Moderate ADn/a−no ARIA-E, moderate ARIA-HPlasma Exchange/Albumen replacement, IVIgsn/aSerum of multiple healthy young volunteersM,O,F/Pn/a[NCT01561053](NCT01561053){#ir0215} (II/III)Grifols Biologicals Inc.[NCT00818662](NCT00818662){#ir0220} (III)Mild to moderate AD+/−−noneNPT088noncontiguous 11−12, 17--25, and 31--40N/A: Human IgG -viral g3p GAIM chimeraO,F/PHuman IgG1[NCT03008161](NCT03008161){#ir0225} (I)Proclara Biosciences[NCT03008161](NCT03008161){#ir0230} (I)Mild to moderate ADn/an/a−[^1][^2][^3]

Evidence has long been accumulating that soluble A*β* and tau oligomers are key pathogenic species that propagate cellular pathology throughout the brain in Alzheimer\'s disease ([@bb0800]; [@bb1465]; [@bb1555]; [@bb0040]; [@bb0615]; [@bb0555]; [@bb0665]; [@bb0180]; [@bb0545]; [@bb0320]; [@bb0955]). In AD patients, the amount of soluble A*β* species correlates more closely with cognitive decline than does amyloid plaque burden ([@bb0930]; [@bb0965]; [@bb1570], see also the comments on tau biomarker abnormalities below). In classic prion disease, soluble oligomers containing roughly 20 PrP molecules are by significant margin the most infectious when inoculated intracerebrally ([@bb1375]), consistent with the notion that high molecular weight species such as plaques have the potential to play a protective role ([@bb1480]). Consistently with these ideas, in brains of autopsy cases with similar amyloid load, the *ratio* of the amount of soluble oligomers over immunohistochemically determined plaque area fully differentiated demented vs. non-demented cases ([@bb0500]).

3.5. Energy landscape framework for conformational selectivity {#s0060}
--------------------------------------------------------------

The selectivity or promiscuity of an antibody can be understood within the context of energy lanscape theory. For an antibody-peptide system, the energy landscape for binding determines the peptide conformation bound by the antibody. For high-affinity binding, the transfer free energy to the bound conformation must be significantly negative, and the overall global structure of the energy landscape will have the topography of a funnel ([@bb1490]; [@bb1110]; [@bb1565], see [Fig. 1](#f0005){ref-type="fig"} ). There is typically a significant amount of entropy loss, which is compensated for by the (negative) enthalpy gain concomitant with binding ([@bb0865]; [@bb0295]; [@bb1005]). The degree to which this cancellation occurs determines how wide or how 'bottlenecked' the funnel is ([@bb1150]). For a wide funnel ([Fig. 1](#f0005){ref-type="fig"} left), dissimilar conformations from the minimum free energy bound conformation also have favorable binding energy: There is more energetic guidance of dissimilar structures towards the minimum energy conformation. Conformations different from the minimal free energy one-- what one may call the "active form"-- are still likely to be bound, with accessible transitions into or out of the active form on a short timescale. This scenario is reminiscent of an induced-fit binding scenario ([@bb0625]; [@bb0370]; [@bb1700]), where although the antibody-peptide complex has a well-defined, most-favorable bound conformation that would be observed e.g. in the crystal structure, it is not particularly energetically selective to a specific conformational species (monomer, oligomer, or fibril/plaque). The binding free energies for alternate conformations of A*β* or tau are still significant.Fig. 1Schematics of energy landscapes of the binding free energy of an epitope to an antibody, as a function of conformational dissimilarity to the bound state structure, which is assumed to be at the lowest point. A conformationally-labile antibody is more prone to induced fit with different alternative conformations of a substrate ligand, and will thus lack binding selectivity (left). A conformationally-selective antibody will be unforgiving to even small conformational differences, which will be costly in terms of binding free energy.Fig. 1

For a steep funnel topography akin to the hole on a golf-green ([Fig. 1](#f0005){ref-type="fig"} right), even slightly dissimilar conformations from the minimum free energy bound conformation do not have favorable binding energy, and so are not bound with significant affinity. The binding scenario is more reminiscent of conformational-selection, wherein the antibody is selective to a small ensemble of conformations consistent with a specific target species.

3.6. Fibril and oligomer polymorphism, and prion-like propagation {#s0065}
-----------------------------------------------------------------

Polymorphism is an inherent aspect of A*β* fibril structures ([Fig. 2](#f0010){ref-type="fig"} ), and ultimately it is a consequence of the absence of any evolutionary selection towards a global free energy minimum, which structured proteins generally possess ([@bb1155]; [@bb1150]). That is, the misfolding energy landscape of the fibril does not have the global topography of a funnel, with a single dominant free energy basin. In contrast to the properties inhereint in well-folded proteins, we would thus expect mutants or alternate isoforms of A*β* (or tau), or altered environmental conditions, to result in alteration of the fibril morphology, which is exactly what has been observed ([Fig. 2](#f0010){ref-type="fig"}). Structural polymorphism underlies prion-like "strains" of A*β* and tau that can propagate their own conformation ([@bb0450]; [@bb1590]; [@bb0825]; [@bb1200]; [@bb0280]; [@bb1085]). An antibody targeting fibrils would have its efficacy limited by fibril polymorphism, in that the antibody may effectively bind and block propagation for one conformational species of fibril, while being ineffective in binding alternate strains. The polymorphism in oligomers is even more profound, rendering structural determination difficult or moot, and making oligomer-selective targets particularly elusive ([@bb1335]; [@bb0890]).Fig. 2A selection of A*β* fibril structures, illustrating their polymorphism. Species (A*β*~40~, A*β*~42~, or the mutant A*β*~40~(E22Δ)) are indicated for each image, along with the PDB entry: 2M4J ([@bb0925]), 2LMN ([@bb1120]), 2MVX ([@bb1310]), 2MXU ([@bb1660]), 5OQV ([@bb0570]), and 2NAO ([@bb1560]). An example of ionic salt-bridges stabilizing the fibril structure is shown for structure 2M4J (D23-K28) in licorice. Structures 2LMN and 2MXU are incompletely resolved: Residues 1--8 are disordered in 2LMN and residues 1--10 are disordered in 2MXU; These residues are thus missing from the respective solid state NMR structural models. For these structures, the missing amino acids have been added and the structures have been equilibrated using all-atom equilibrium molecular dynamics. Consistent with the solid-state NMR data, these peptide regions remain disordered when molecular dynamics is implemented for these structures. For other structures such as 2M4J and 2NAO, these N-terminal peptide regions remain structured and are largely *β*-sheet.Fig. 2

With the above caveats acknowledged, an oligomer-selective antibody that was administered at the appropriate time would have the potential to block and neutralize some or all toxic, propagating species of misfolded protein. Prion-like propagation for both A*β* and tau is supported by multiple lines of in vitro and in vivo Evidenc*e. tau* prion-like propagation is discussed further below in the context of tau therapies. Here we focus on the evidence for A*β* prion-like propagation.

It has been noted that A*β* peptide exhibits many of the hallmarks of classical prionogenesis, including the adoption of *β*-rich architectures that are often resistant to proteolytic or denaturing forces, amyloidogenic polymerization that may template the misfolding and aggregation of healthy protein and which results in both structurally and functionally variable "strains", and systematic spread along neural connective networks that facilitates intercellular self-propagation ([@bb1225]; [@bb0340]; [@bb1585]). That said, there is no current evidence of host-to-host transmission and systemic uptake of toxic A*β* species in the same sense as for the canonical prion diseases (see however the comments below). We thus refer to the intercellular propagation of misfolded A*β* as "prion-like".

[@bb0990] have observed that brain extract from either human AD patient or APP23 transgenic mice induced numerous A*β* deposits in APP23 murine hosts beginning \~2 months after injection. The same was not observed for WT donors or WT hosts, implying that misfolded A*β* needed to be present in the donor, and a host A*β* reservoir that is induction-competent was required for deposition of endogenous A*β*. The amyloid-inducing activity of extracts was prevented by immunodepletion of A*β*, and attenuated by pre-mixing with A*β* -specific antibodies, indicating that A*β* itself is the key species inducing deposition. Similarly, weekly interperitonial passive immunization following injection blocked amyloid deposition, reinforcing the potential efficacy of an A*β* passive immunotherapy. Interestingly, pretreatment with formic acid, which does not dissociate high molecular weight species, but which does dissociate oligomers, completely prevented amyloid deposition of endogenous data.

In the study of [@bb0990], no amyloid deposition was observed for aged, synthetic A*β* ~40~/A*β* ~42~ preparations, synthetic oligomers, or even synthetic A*β* mixed with brain extract from WT mice. This observation, coupled with the above-mentioned blocking activity of A*β* antibodies, suggests the presence of polymorphic conformations with significantly variable and strain-dependent seeding efficacy, reminiscent of prions. Similarly, intracerebral inoculation of hAPPwt mice---which do not develop amyloid aggregates during their lifespan---with AD patient brain extract also induced pathological A*β* deposition, after \~10 months ([@bb1010]). Extending the prion analogy, peripheral inoculation intraperitoneally with A*β* -containing brain homogenates from APP23 and APP-PS1 transgenic mice into either APP23 or R1.40 transgenic mice aged 1--2 months showed induction of cerebral *β*-amyloidosis in a pattern consistent with the entry of A*β* -templating seeds at multiple locations in the brain ([@bb0485]).

The inability of synthetic A*β* preparations to induce cerebral amyloid deposition in the study of [@bb0990] is a cause for justifiable concern. However, more recently, [@bb1410] have found that *β*-amyloid deposition can be induced by synthetic A*β* aggregates. In their study, either A*β* ~40~ or mutant A*β* ~40~(S26C)---which makes covalently-bonded dimers---was incubated to form aggregates, which in both cases contained both fibular and globular structures. Intracerebral inoculation of fairly high concentrations of either of these synthetic preparations induced amyloidogenic deposition of endogenous A*β* in bigenic APP23:Gfap-luc mice (these are mice with the Swedish double mutation of human APP, and a luciferase reporter under control of a glial fibrillary acidic protein (Gfap) promoter).

Induced A*β* amyloid deposition has been observed in individuals treated during childhood with cadaveric pituitary-derived growth hormone (c-hGH), which resulted in iatrogenic CJD ([@bb1430]; [@bb0230]), but with additional A*β* amyloid pathology ([@bb0760]). The samples of human c-hGH that induced A*β* pathology were shown by antibody capture and detection to contain high levels of A*β* ~40~, A*β* ~42~, and tau protein ([@bb1195]). This association between peripheral administration and brain deposition of A*β* was subsequently supported in APP NL-F knock-in mice ([@bb1195]). These mice were intracerebrally inoculated with the same A*β* and tau-containing samples of c-hGH that were administered to a subset of the above iatrogenic CJD patients. Intraperitoneal injections, though potentially very interesting, appear not to have been performed. The inoculated mice subsequently developed seeded formation of A*β* plaques and cerebral A*β* -amyloid angiopathy (CAA). Together, the above results provide strong support for prion-like propagation of A*β* within a single host, and in rare cases between hosts under unusual environmental exposure.

4. Passive immunotherapies for A*β* {#s0070}
===================================

[Table 1](#t0005){ref-type="table"} lists the A*β* therapeutics currently in clinical trials, along with their epitopes, immunization strategies, selectivity for monomer (M), oligomer (O), or fibril/plaque (P) species. Also included are antibody backbone isotype, current clinical trials and sponsor, and results for completed trials. For antibodies currently or recently in clinical trials with known epitopes on A*β*, [Fig. 3](#f0015){ref-type="fig"} shows the locations of those epitopes on the primary sequence. We begin by discussing antibodies whose development was relatively early historically, and/or whose clinical trials have been discontinued, moving to antibodies that have been developed more recently.Fig. 3Epitope locations on the primary sequence of A*β*, for antibodies currently or recently in clinical trials. Black bars indicate epitope locations; gray bars indicate presumptive epitopes that likely subsume the actual epitope as a subset of the gray region. Gradient filling for MEDI-1814 represents the incompletely characterized epitope, but with known A*β*~42~ selectivity. Gantenerumab and NPT088 both have discontiguous epitopes on A*β*. Magenta region on the epitope for donanemab represents pyroglutamate at amino acid position 3. Amino acids in the primary sequence of A*β* are colored as follows. Red: negatively charged; Blue: positively charged; Green: aromatic; Yellow background: hydrophobic. The significant hydrophobicity and absence of aromatic residues in the C-terminal region is noteworthy. Specific epitope locations are listed in [Table 1](#t0005){ref-type="table"}. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3

4.1. Bapineuzumab {#s0075}
-----------------

The murine version of this antibody (3D6) was generated by active immunization of mice with sequence ^1^DAEFR^5^ of A*β* conjugated to sheep anti-mouse immunoglobulin ([@bb0780]). The co-crystal structure of bapineuzumab (4HIX.pdb, see [Fig. 4](#f0020){ref-type="fig"} ) in complex with a fragment of A*β* (residues 1--6) indicates a bound structure with a helical conformation of the epitope ([@bb1000]). The side chains of the acidic residues D1 and E3 on A*β*, as well as the positive N-terminus and aromatic ring of F4, all point into the binding cleft.Fig. 4Antigen-binding regions of antibodies to A*β* in clinical development, with published co-crystal structures to their epitopes. Antibodies, Protein Databank entry, and epitopes are, from top left to right: aducanumab (PDB [6CO3](pdb:6CO3){#ir0005}, structured epitope amino acids 2-7) bapineuzumab (PDB [4HIX](pdb:4HIX){#ir0010}, structured epitope aa1-6) crenezumab (PDB [5VZY](pdb:5VZY){#ir0015}, structured epitope aa13-24), gantenerumab (PDB [5CSZ](pdb:5CSZ){#ir0020}, structured epitope aa1-10), ponezumab (PDB [3U0T](pdb:3U0T){#ir0025}, structured epitope aa30-40.) solanezumab (PDB [4XXD](pdb:4XXD){#ir0030}, structured epitope aa16-26). Interacting aromatic rings are rendered in magenta for visualization. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 4

In mouse models with \>10-fold expression of APP over endogenous levels (PDAPP mice), 3D6 was shown to opsonize amyloid plaques, i.e. bind, decorate, and facilitate their clearance, as well as improve synaptic function and cognitive performance in behavioral assays ([@bb0145]; [@bb1400]; [@bb0830]).

Bapineuzumab was the first monoclonal antibody to enter human testing after termination of the AN1792 active vaccination trial. Patients in these trials did not demonstrate significant cognitive benefits ([@bb1265]), and MRI scans revealed significant adverse issues, including ARIA-H and ARIA-E ([@bb1515]). Interestingly, a retrospective review of MRI scans from the phase 2 studies revealed that about 7% (15) of participants had developed ARIA-E during the trials, but remained undetected (10% had ARIA that was detected). 13 of these 15 participants continued to receive additional immunotherapy infusions while ARIA-E was present, and these patients did not develop additional associated symptoms ([@bb1395]). The occurrence of ARIA was strongly related to the ApoE-*ε*4 copy number and arose predominantly during the first three infusions. All phase 3 trials with bapineuzumab were terminated in 2012 when phase III trials [NCT00575055](NCT00575055){#ir0420} and [NCT00574132](NCT00574132){#ir0425} showed no clinical benefit ([@bb1270]). This decision was not based on any new safety concerns.

Nevertheless, a variant of Babineuzumab with reduced Fc-receptor-mediated effector function, AAB-003, has been developed, and two phase I clinical trials ([NCT01193608](NCT01193608){#ir0430},[NCT01369225](NCT01369225){#ir0435}) to assess safety and tolerability have been completed ([@bb0420]). To reduce binding of Fc*γ*R and complement C1q, three amino acid mutations have been introduced in the hinge region (L234A/L235A/G237A). Although these mutations are not in the complement binding region, effector activity was evidently reduced: The dose where ARIA-E was observed for AAB-003 was higher compared to bapineuzumab.

4.2. Solanezumab {#s0080}
----------------

The murine precursor to solanezumab, m266, was generated by immunization of mice using A*β* peptide amino acids (13--28), conjugated to anti-mouse CD3*ε* antibody as an immunogen ([@bb1300]). Solanezumab is the humanized monoclonal IgG1 antibody of m266, with epitope in the mid-region of A*β*, spanning residues 16--26 (PDB structure 4XXD.pdb, see [Fig. 4](#f0020){ref-type="fig"}, [@bb0365]). The conformation of the epitope is partly extended and partly helical (from F20-S26). Residues pointing into the binding cleft of the antibody are K16, F19, F20, E22, and D23 (F19, F20 are shown in magenta in [Fig. 4](#f0020){ref-type="fig"}). Solanezumab exhibits strong binding to monomers of A*β* ~40~ or A*β* ~42~, with affinity in the low pM range. It also exhibits cross-reactivity to other proteins from brain homogenates ([@bb1580]). However, solanezumab has been thought to deplete brain A*β* stores by sequestering A*β* monomers in the blood and thus shifting the brain-blood equilibrium (the peripheral sink hypothesis, see e.g. [@bb0425]). In humans, solanezumab treatment results in significant increases of both A*β* ~40~ and A*β* ~42~ concentrations in plasma and CSF. Subsequent observations have cast doubt on the peripheral sink mechanism, since a decrease in A*β* efflux due to m266 was observed in those experiments ([@bb1665]), suggesting that the beneficial effect of m266 is due to inhibition of A*β* forming oligomers and fibrils in the brain. Additionally, antibody binding to A*β* in plasma substantially increases the half-life of A*β*, from approximately 5 min for free peptide, to up to several days for bound A*β* ([@bb0560]). While not ruling out the peripheral sink hypothesis, such stabilizing effects must be disentangled from the potential effects of enhanced efflux from the brain.

Results from two large phase 3 trials involving over 2000 patients and completed in 2012 revealed no significant difference in cognition and memory between the solanezumab-treated and the placebo group ([@bb0455], see [Table 1](#t0005){ref-type="table"}). However, subsequent analysis of subgroups in these trials revealed a statistically significant slowing in decline for some cognitive measures (34% slowing vs. placebo for ADAS-Cog~14~ and MMSE) and a significant slowing for some functional measures (18% slowing vs. placebo for ADCS-iADL), for the subgroup of mild AD ([@bb1360]). This suggested positive therapeutic effects may be seen if administered at earlier stages of progression. Follow-up phase 3 clinical trials (Expedition 3, [NCT01900665](NCT01900665){#ir0440}) in mild AD patients showed no significant benefits over placebo however, and were terminated. Currently, solanezumab is administered every 4 weeks in the Asymptomatic Alzheimer\'s Disease trial (A4 trial, [NCT02008357](NCT02008357){#ir0445}), which has enrolled cognitively normal people with amyloid accumulation, to test whether earlier administration may be effective as a preventative measure. Based on modest but encouraging results from previous clinical trials, the dosage was quadrupled from 400 to 1600 mg in June 2017.

4.3. Ponezumab {#s0085}
--------------

Ponezumab is a humanized IgG2*δ*A antibody with two mutations to minimize potential immune effector function (A33S and P331S). Epitope mapping by overlapping peptide scans localizes the epitope to residues 30--40 of A*β* ~40~ ([@bb1160]). The co-crystal structure (PDB [3U0T](pdb:3U0T){#ir0450}.pdb, [Fig. 4](#f0020){ref-type="fig"}) shows an extended, linear conformation of the epitope residues 30--40, with the C-terminal more buried than the N-terminal portion ([@bb1160]). The C-terminal carboxylic acid on residue 40 is critical to ponezumab binding activity: The antibody does not bind A*β* ~42~.

ELISA binding assays along with immunohistochemistry show that ponezumab is not species-selective, binding to monomers, oligomers, and fibrils of A*β* ~40~ ([@bb1160]). Like solanezumab, it is hypothesized to deplete brain A*β* stores by sequestering A*β* in the blood and thus shifting the brain-blood equilibrium (the peripheral sink hypothesis, see e.g. [@bb0425]).

Ponezumab shows low to moderate ARIA-H and low ARIA-E risk ([@bb0875], [@bb0870]). Although ponezumab revealed a favorable safety profile, two subsequent phase 2 studies revealed no significant clinical benefit, and development of ponezumab for AD was discontinued.

4.4. Crenezumab {#s0090}
---------------

In the development of the murine precursor to crenezumab (MABT5102A or mMABT), liposomes containing anchored peptides of A*β* ~1−16~ were used to immunize mice ([@bb1135]; [@bb0015]). Liposome presentation may present the epitope in *β*-sheet like conformations. Unusually, there was a shift in the binding epitope position of mMABT, from the region presented in the immunization peptide, to residues 13--24 on A*β* ([@bb1135]). An IgG4 backbone isotype was selected for low effector function; The mutation S228P also appears to be implemented, which stabilizes inter-heavy chain disulfide bridges preventing "half-molecule" exchange ([@bb1370]).

The A*β* epitope comprising residues 13--24 is fairly linearized in the co-crystal structure 5VZY.pdb ([@bb1505], see [Fig. 4](#f0020){ref-type="fig"}). The antibody has high affinity for higher molecular weight species such as fibrils, plaques, and oligomers, while having low affinity for monomers ([Table 1](#t0005){ref-type="table"}).

In phase II trials, crenuzumab lowered oligomer levels in CSF for the majority of patients (89% receiving subcutaneous doses and 86% receiving intravenous doses) ([@bb1690]), but PET amyloid load was not lowered, and no significant treatment-related change in cognitive outcome was observed ([Table 1](#t0005){ref-type="table"}). Incidence of ARIA was low, which, along with the high ARIA incidence of other amyloid-clearing antibodies, suggests that activation of effector mechanisms may be a key event in the clearance of plaque amyloid. Phase 3 trials were halted in January 2019, as interim analyses indicated that the trial was unlikely to reach its primary endpoint of slowing cognitive decline according to the CDR-SB test.

Motivated by the need for preventative intervention to modify the future course of the disease, the Alzheimer Prevention Initiative (API) is currently studying the efficacy of crenezumab vs. placebo for 300 asymptomatic presenilin-1 E280A mutation carriers, who are autosomal-dominant for AD ([@bb1450]). This study will inform on the efficacy of crenezumab to either delay the onset, slow the decline, or prevent cognitive impairment in individuals with preclinical autosomal-dominant AD.

4.5. Gantenerumab {#s0095}
-----------------

Rather than using an active immunization step, gantenerumab is a fully human IgG1 antibody selected from synthetic human combinatorial antibody libraries (HuCALs, [@bb0845]) using phage display, followed by in vitro affinity maturation using CDR cassette exchanges ([@bb1405]). In the context of antibodies targeting influenza hemagglutinin, phage display libraries from isolated B cells have been used to isolate rare lead antibodies that were not detected directly by next-generation sequencing ([@bb1215]).

Peptide screening assays ([@bb0200]) indicate that gantenerumab is capable of binding two discontiguous regions of A*β*, with highest affinity at residues 2-11 and 18-27. Such a binding mode to separate epitopes may allow binding to N-terminal truncated A*β* species, and facilitate avidity-enhanced binding on the fibril surface ([@bb0200]), potentially involving both variable domain arms of the antibody. It also implies a flexible binding pocket on the antibody that is capable of binding several sequences. This has implications for both the selectivity of the antibody for distinct A*β* species (the antibody binds all species, [Table 1](#t0005){ref-type="table"}), and the potential for off-pathway reactions. The structure of the antibody-epitope (PDB [5CSZ](pdb:5CSZ){#ir0455}.pdb) shows amino acids 1--10 of A*β* are extended in a linearized conformation (see [Fig. 4](#f0020){ref-type="fig"}). Gantenerumab exhibits sub-nanomolar binding affinity to A*β* ~40~ fibrils; the dissociation constants for A*β* ~40~ fibrils, oligomers, and monomers are 0.6 nM, 1.2 nM, and 17 nM respectively ([@bb0200]).

Thus, gantenerumab preferentially interacts with aggregated A*β*, and may facilitate degradation of opsonized amyloid plaques by recruiting microglia and activating phagocytosis ([@bb0145]). These early studies indicated that even modest levels of peripherally administered antibody were able to cross the blood-brain barrier and enter the CNS, bind to plaques, and induce clearance of amyloid. Treatments combining BACE inhibitor R7129 with gantenerumab have shown an additive effect between the two drugs in APP transgenic mouse models, in that the combination reduced A*β* levels and plaque burden more strongly than either treatment alone ([@bb0750]). In phase I clinical trials, gantenerumab was found to reduce plaque burden in AD patients, prompting further trials, including two ongoing additional phase III trials for patients with prodromal ([NCT01224106](NCT01224106){#ir0460}) and mild ([NCT02051608](NCT02051608){#ir0465}) AD ([Table 1](#t0005){ref-type="table"}). As well, gantenerumab and solanezumab have both been tested in patients carrying autosomal-dominant mutations for AD in the DIAN-TU clinical trial ([NCT01760005](NCT01760005){#ir0470}), discussed further below.

4.6. Donanemab (LY3002813) {#s0100}
--------------------------

A disease-modified form of A*β* peptide (A*β* ~*p*3−42~) may occur through protease-cleavage of the first two amino residues, followed by cyclization of the side chain of glutamic acid residue E3 to pyroglutamate. This cyclization occurs either spontaneously or by the enzyme glutaminyl cyclase. A*β* ~*p*3−42~ plays an important role in early AD pathology by seeding toxic oligomeric species ([@bb1635]), and A*β* ~*p*3−42~ deposits preferentially in amyloid plaques. There has thus been impetus to generate antibodies targeting A*β* ~*p*3−42~ as plaque-specific therapeutics. The above observations have also motivated drug development for glutaminyl cyclase inhibitors ([@bb1285]), which are currently in clinical trials.

Donanemab is a humanized IgG1 antibody developed from the murine IgG2a antibody mE8 ([@bb0430]). mE8 is raised by actively immunizing mice with A*β* ~*p*3−42~. Mutational analysis on A*β* shows that the epitope involves the truncated N-terminal residues pE3-D7. mE8 thus does not bind full-length A*β* (or full-length A*β* ~42~), and also shows about 300-fold greater affinity to pE3 vs. E3 in truncated A*β* ~3−42~. mE8 can thus be thought of as binding a disease-modified N-terminus.

Unfortunately, donanemab is itself strongly immunogenic; Nearly all (≈90%) patients who received the therapy mounted an immune response against it ([NCT01837641](NCT01837641){#ir0475}, [clinicaltrials.gov](http://clinicaltrials.gov){#ir0480}). This immunogenicity poses no serious health concerns however and patients were continued on trials. Administering the antibody resulted in significant decreases in brain amyloid burden---a six month course of 20 mg/kg dropped amyloid load by an average of 70 centiloid. Specifically, on a 100-point centiloid scale, young amyloid-negative subjects aged 31 ± 6 years have an average centiloid value of zero, and "typical" diagnosed AD patients with questionable dementia to mild cognitive impairment according to CDR-SB tests would average approximately 100 ([@bb0840]). About 25% of patients taking gantenerumab developed ARIA-E, though mostly asymptomatic.

The latest phase II trial ([NCT03367403](NCT03367403){#ir0485}) consists of 3 arms: One with both donanemab and the BACE inhibitor LY3202626, one with donanemab and placebo, and one with two placebos. The arm of this trial involving BACE inhibitor was discontinued in October 2018, however the other two arms remain ongoing.

4.7. Aducanumab {#s0105}
---------------

Aducanumab is a fully human IgG1 monoclonal antibody derived from a blood lymphocyte library that was collected from elderly patients who showed either no signs of cognitive impairment or unusually slow cognitive decline. It thus relies on the assumption that these patients would generate antibodies protective against AD. B cells are isolated from peripheral blood lymphocyte preparations by anti-CD22-mediated sorting, and were cultured on gamma-irradiated human peripheral blood mononuclear cell feeder layers. Supernatants from these patients\' B-cells were screened for binding to A*β* plaques in tissue sections, in vitro binding to A*β* ~40~ and A*β* ~42~, and lack of binding to full-length APP ([@bb1345]).

Aducanumab binds to soluble A*β* aggregates and insoluble fibrils with \>10,000-fold selectivity over monomers ([@bb0240]). Weak binding to monomers has also been observed ([@bb0105]; [@bb1380]). In the co-crystal structure with aducanumab (6CO3.pdb, [Fig. 4](#f0020){ref-type="fig"}), the epitope, consisting of residues 2--7 of A*β*, adopts an extended conformation ([@bb0105]). The alanine residue A2 in A*β* points away from the antibody, and so is not included in the putative epitope in [Table 1](#t0005){ref-type="table"}. The complex is stabilized by a cation-pi interaction ([@bb0460]) between an arginine on the antibody and phenylalanine F4 on A*β*, which likely contributes to the high binding affinity. Otherwise, the binding pocket is relatively shallow compared to other N-terminal binding antibodies such as bapineuzumab and gantenerumab.

Biogen initially reported in March 2019 that aducanumab did not meet its primary end points for slowing cognitive decline in phase III clinical trials ([NCT02477800](NCT02477800){#ir0490} (ENGAGE), [NCT02484547](NCT02484547){#ir0495} (EMERGE)), although the antibody was effective at clearing A*β* plaque from patients, likely through Fc*γ*R-mediated phagocytosis by microglia ([@bb1345]). The high affinity for abundant, insoluble A*β* along with significant effector function of the antibody gave rise to a 37% or 41% risk of ARIA-E,H in the two highest dosage groups ([@bb1345]). The trial recruited patients in the early symptomatic phase of AD, however it appears that this stage is already late in deriving clinical benefit by targeting A*β*, and tau pathology and neuroinflammation may be the predominant neurodegenerative drivers at this stage.

Biogen initially halted development of aducanumab in March 2019 after the preliminary data from the EMERGE and ENGAGE trials suggested it would not meet primary endpoints. The initial conclusion that there was a failure to show cognitive benefit indicated that removal of amyloid was ineffective---at least on the time scale of 2--3 years---for patients who have progressed to mild or moderate stages of the disease ([@bb1330]). It should be noted however that these results do not preclude drugs such as aducanumab as potentially effective in prodromal cases of AD. There was also the speculation that, while on average there appeared to be no significant cognitive benefit, some patients could have experienced favorable effects.

On October 22, 2019, Biogen announced that the interim futility analysis was incorrect, and that subsequent analysis of a larger data set instead showed EMERGE had in fact met its primary endpoint (data was presented at the 2019 CTAD conference ([@bb0620])). Specifically, patients on the highest dose (titrated to 10 mg/kg over 26 weeks) had a significant reduction in decline in cognition, according to CDR-SB test--the primary endpoint. As well, the high-dose group declined less on secondary cognitive endpoints such as the MMSE, ADAS-Cog, and ADCS-ADL-MCI tests. The lower dose group (titrated to either 3 mg/kg (ApoE-*ε*4+) or 6 mg/kg (ApoE-*ε*4−)) appeared to show slowing of cognitive, but the changes did not reach statistical significance.

Oddly, the cognitive trajectories in the ENGAGE trial appear significantly different from those in the EMERGE trial, and the ENGAGE study arm did not meet its primary endpoint. This was explained through differences in the enrollment between the study arms during the dosing titration increase. Unlike the EMERGE data, the ENGAGE data also did not show dose response for phospho-tau and total tau biomarkers. That said, a subgroup analysis (post protocol version 4) of patients in both arms who had received 10 or more 10 mg/kg doses of aducanumab did show dose-dependent and statistically-significant reduction in CDR-SB-measured cognitive decline. Based on this latest data and the revised analysis, eligible patients from phase III trial arms have been asked to return for continued dosing and testing, and Biogen has announced plans to apply in early 2020 for regulatory approval for aducanumab in the U.S.

4.8. SAR-228810 {#s0110}
---------------

SAR-228810 is a humanized IgG4 antibody based on murine antibody 13C3. 13C3 was itself raised by immunization using incubated synthetic A*β* ~42~, which forms multimers/oligomers of various size ([@bb1305]). 13C3 was selected by screening for antibodies specific to protofibrillar A*β* ~42~ (≈670kDa or ≈150 A*β* ~42~ molecules) over low molecular weight (LMW) species (\<17kDa or 3--4 A*β* ~42~ molecules). SAR-228810 binds to soluble protofibrils and insoluble fibrils of A*β*.

The precise epitope location has not been determined/disclosed, but is likely in the N-terminal region between residues 4--20 ([@bb1230]). The antibody is conformationally selective: SAR-228810 does not bind appreciably to soluble A*β* monomers or low molecular weight A*β* complexes. It does bind amyloid plaques, but not to diffuse, non-*β*-sheet deposits of A*β* ([@bb1175]). The antibody binds to protofibrillar and fibrillar aggregates with approximately 100-fold selectivity over A*β* monomer in ELISA assays.

SAR-228810 has two mutations on a human IgG4 backbone, one (S241P) that promotes inter-heavy chain disulfide bridges preventing "half-molecule" exchange ([@bb0090]), and another (L248E) that significantly reduces effector function ([@bb1235]). The antibody has low binding affinity for activating Fc*γ*Rs on human microglia, and shows no binding to complement C1q, which is a pro-inflammatory component of the innate immune system ([@bb1170]). Consistently, in phase I clinical trials ([NCT01485302](NCT01485302){#ir0500}) of 44 single-dose and 48 multiple-dose patients ([@bb1530]), SAR-228810 was well-tolerated, an upper limiting dose as determined by adverse events was not reached, there were no reported cases of ARIA-E, and there was only one reported case of ARIA-H (a single-dose patient). No additional trials have been scheduled to date however.

4.9. BAN-2401 (Lecanemab) {#s0115}
-------------------------

Patients carrying the E22G (APP E693G) mutation of A*β* (the "Arctic" mutation) show particularly high levels of A*β* protofibrils ([@bb1050]), abundant parenchymal plaques but without a dense amyloid core ([@bb0155]), and are autosomal-dominant for early-onset AD. ([@bb1600]). Murine antibody mAb158 was generating by immunizing mice against E22G mutant A*β* protofibrils ([@bb1495]). Soluble protofibrils are an abundant toxic species in AD brains ([@bb1320]). mAb158 binds to protofibrils with much higher affinity than monomers ([@bb0495]), and reduces protofibrils in the brain and CSF of transgenic mice expressing both the above Arctic mutation and the "Swedish" double mutation in APP (K670N/M671L; tgArc-Swe mice) ([@bb1495]). Studies in embryonic mouse-derived co-cultures of astrocytes, neurons, and oligodendrocytes show that mAb158 can protect neurons from A*β* ~42~-induced death by preventing the accumulation of A*β* through astrocyte-uptake ([@bb1390]).

BAN-2401 is the humanized version of the mAb158. In phase 2b trials, the antibody reduced plaques by 93% in patients in the highest dosage arm ([@bb1425]). This is consistent with immunohistochemical observations that the antibody binds to plaque as well as high molecular weight oligomer ([@bb1180]). As a likely consequence to plaque binding however, ARIA-E was observed in 14.6% of APOE*ε*4 carriers in the largest, most-frequent dosage arm (10 mg/kg bi-weekly). In this dosage arm however, cognitive decline was slowed by 47% on the ADAS-Cog, and by 30% on the ADCOMS ([@bb1425]). In a controversial decision arising from safety concerns related to ARIA, european regulators limited the number of APO*ε*4 carriers in the highest most frequent dosage arm compared to the placebo arm and other dose groups, partway through the trial. The concern arising over this imbalance was then whether it contributed significantly to the appearance of a benefit in the high dosage arm, which would then be artifactual. Subsequent independent statistical analysis of subgroups ([@bb0440]) has since indicated that the cognitive benefits were statistically significant, and that because in fact APOE*ε*4 carriers responded better to the drug, the above regulatory limitations may have negatively (rather than positively) affected the statistical significance, leading to a potential underestimate of the drug\'s effects ([@bb1535]; [@bb0065]).

4.10. MEDI-1814 {#s0120}
---------------

MEDI-1814 is a fully human antibody optimized from a clone identified from phage library selections against A*β* ~42~ ([@bb0175]). MEDI-1814 binds selectively to the C-terminus of A*β* ~42~ with very high affinity ≈50-300 pM ([@bb0175]). The epitope is broadly characterized between residues 29--42 ([@bb0585]), but selective to A*β* ~42~ in that the antibody does not engage A*β* ~40~ ([@bb0190]). The epitope thus likely involves at least I41, A42, and possibly the charged C-terminus of A42. The antibody appears to be selective to low molecular weight species, primarily monomers. In the CSF of rats and monkeys, MEDI-1814 reduced free, antibody-unbound levels of A*β* ~42~, while increasing total A*β* ~42~ ([@bb0175]), indicating target engagement. There is no co-crystal structure reported to date.

MEDI-1814 has an IgG1 backbone, but has a triple mutation in its Fc tail to reduce effector function. Consistently, initial phase 1 results ([NCT02036645](NCT02036645){#ir0510}, [clinicaltrials.gov](http://clinicaltrials.gov){#ir0515}) report no serious adverse effects, and MRI scans showed no evidence of ARIA ([@bb1090]). Participants in phase I clinical trials showed also no signs of either ARIA-H or ARIA-E.

4.11. KHK6640 {#s0125}
-------------

KHK6640 is a humanized IgG4 antibody with mutations to limit effector function. CSF analysis indicated that the amount of KHK6640-bound A*β* oligomers increased in a dose-dependent manner, showing oligomer target engagement ([@bb0250]; [@bb1355]). About 7% of the patients were immunoreactive to the antibody. Unfortunately, there is little or no published preclinical data on this antibody or its murine precursor.

4.12. Plasma exchange therapy, albumen replacement, and IVIg {#s0130}
------------------------------------------------------------

Intravenous immunoglobulin polyclonal cocktails (IVIgs) contain a small fraction of polyclonal antibodies directed against A*β*, and there is some evidence that they may enable clearance and reduce synaptic toxicity caused by A*β* ([@bb1435]). IVIgs have been examined for the treatment of many diseases including AD ([@bb0920]). They have an established safety record for patients with immunodeficiency or autoimmune conditions.

Previous trials involving IVIgs (Gammagard Liquid) have given overall negative results ([NCT00818662](NCT00818662){#ir0520}, ([@bb1240])). Preliminary results from the moderate AD subgroup who were ApoE4^+^ taking the higher 400 mg/kg dose showed positive cognitive benefits over the placebo group. However, the trial was not powered to detect statistical significance in any of the subgroups. As well, Florbetapir PET amyloid imaging showed a modest reduction in fibrillar amyloid, the type deposited in amyloid plaques, although the study was also not powered to confirm this effect.

More recently, phase 3 clinical trials have been completed involving treatment with plasma exchange (PE) plus low or high dose therapeutic albumin replacement, with or without IVIgs (under the trade name Flebogamma) (the Alzheimer\'s Management by Albumin Replacement (AMBAR) trial, [NCT01561053](NCT01561053){#ir0525}, [@bb0185])). The rationale is based on the hypothesis that A*β* may be bound to albumin and the complex then circulates in plasma, so extracting this plasma could flush amyloid from the brain, similar to the peripheral sink hypothesis but without potential confounding effects of stabilized bound complexes in the blood. As well, albumin has been shown to have antioxidant, immune-modulatory, and anti-inflammatory properties ([@bb0540]; [@bb0150]), which may diminish neuroinflammation.

The AMBAR study revealed some impressive data that at the very least warrants further studies. Perhaps consistently with the performance of IVIgs in previous clinical trials for AD, there was no significant effect on whether PE was accompanied with IVIGs; There was also no significant effect on whether PE also had low or high dose albumin replacement. Cognitive endpoints such as CDR-SB showed significant difference from placebo and even potential improvement among mild AD participants ([@bb1095]). Among moderate AD participants there was a statistically significant reduction in cognitive decline by CDR-SB. There were also significant differences in both groups according to psychometrics such as the Clinical Global Impression of Change (ADCS-GCIC). Among moderate but not mild AD participants, activities of daily living (ADCS-ADL) and neuropsychological Cognitive subscale (ADAS-Cog) were also significantly improved relative to placebo (61% less decline) ([@bb1095]).

4.13. NPT088 {#s0135}
------------

Many bacteria form functional amyloid assemblies on their cell surface, which aid in biofilm formation and other community behaviors involving cell-cell interactions ([@bb1705]). These amyloids can enhance virulence, facilitate cell adherence and invasion, and aid the survival and spread of the pathogen ([@bb0520]). M13 is a filamentous bacteriophage that recognizes amyloids on the bacterial cell surface through a two-domain fragment of the phage capsid protein g3p (gene 3 protein). NMR studies have shown that g3p can also recognize A*β* fibrils, predominantly through an epitope involving the middle and C-terminal residues of A*β* ([@bb0860]).

NPT088 is an antibody made from a fusion of g3p with the Fc region of a human IgG1. The chimeric antibody targets many different amyloids, including amyloid beta, tau, alpha-synuclein, antibody light chain, and transthyretin ([@bb0985]). The recognition portion is thus referred to as a general amyloid interaction motif (GAIM). Based on the ability of the antibody to remove A*β* plaque, reduce phospho-tau pathology, and improve cognitive performance in mouse models ([@bb0895]), NPT088 has moved into clinical trials (phase I, [NCT03008161](NCT03008161){#ir0530}). A second candidate utilizing GAIM recognition (NPT189) is also currently in phase I clinical trials ([NCT03610035](NCT03610035){#ir0535}).

4.14. Selected preclinical A*β* antibodies {#s0140}
------------------------------------------

Similar to donanemab, the antibodies 8C4 and 9D5, generated by immunizing mice with A*β* ~*p*3−38~, are selective for A*β* ~*p*3−42~: They bind to A*β* ~*p*3−42~ but show no binding signal to A*β* ~42~ ([@bb1640]). Furthermore, 9D5 only binds to low molecular weight A*β* ~*p*3−42~ oligomers: There was no reactivity observed to monomers or dimers, and immunohistochemistry showed intraneuronal imunoreactivity and/or vascular staining, but not broad plaque-staining as observed for other antibodies ([@bb1640]). Given the early dates of these initial findings, the prospects of the above antibodies entering clinical trials are uncertain, but would appear to be unlikely.

An A*β* oligomer-selective, humanized IgG2 antibody ACU193 (also called 19.3) was modified from a mouse monoclonal IgG1 antibody 3B3 (also known as ACU-921). 3B3 was obtained from mice immunized with synthetic A*β* -derived diffusible ligands (ADDL) of A*β* ~42~ ([@bb0005], [@bb0010]). The antibody shows preferential binding affinity for 3-24mers of A*β*, vs. monomeric A*β* or A*β* plaque, and no visible binding to vascular amyloid. In fact, the binding epitope sequence of 3B3 was not able to be determined by linear epitope mapping in ELISA, as the antibody failed to bind any members of the overlapping peptide set, even at high concentrations. However it could bind A*β* 1--20 peptide, which was used as a positive control. Similarly, binding of 3B3 to ADDLs was not blocked by short linear peptides of ≤ 10 amino acids in A*β* ~42~, but interestingly binding was blocked by A*β* 1--28, indicating an epitope based on a conformational structure also found in A*β* 1--28 fragments (and possibly also A*β* 1--20). 3B3 was observed to be effective in blocking the assembly of ADDLs, as observed through fluorescence quenching of flourescein-labelled oligomers by unlabelled monomers, and fluorescence polarization increase as oligomers assembled ([@bb0005], [@bb0010]). The murine precursor 3B3 was able to restore long-term potentiation in rat hippocampal slices ([@bb0325]), and to reverse the dysregulation of cytosolic calcium concentration ([@bb1575]).

PMN310 is a humanized IgG4 antibody that binds a conformational epitope consisting of ^13^HHQK^16^, specifically when presented on low-molecular weight oligomers and protofibrils. The antibody shows no apparent binding to A*β* monomer, amyloid plaque, or vascular deposits ([@bb0525]). This is a potential advantage to avoid target distraction by more abundant monomers, and if clearing plaque does not correlate with cognitive benefit. The epitope was predicted based on computational modelling of A*β* oligomers, by using molecular dynamics to find the regions most-likely to be solvent-exposed in a protofibril ([@bb1130]; [@bb0265]). Immunization proceeded by conjugating cyclic peptides containing the epitope to KLH as an immunogen, wherein the cyclic peptide constructs were chosen based on oligomer-selective epitope scaffolding ([@bb1380]). Immunohistochemical studies show that PMN310 exhibits essentially no binding to A*β* plaque in AD brain samples, supporting greater selectivity of PMN310 to A*β* oligomers and reduced risk of ARIA-related adverse effects compared to other antibodies currently in clinical development such as aducanumab and BAN2401. The murine precursor muPMN310 inhibited A*β* ~42~ aggregation in ThT assays, and increased viability of neurons in in vitro MTT metabolic assays ([@bb0525]). PMN310 was also observed to block the effects of toxic oligomers on short-term memory loss in mice, as assessd by the novel object recognition test ([@bb0805]; [@bb0525]).

5. Tau immunotherapy {#s0145}
====================

Tau protein binds to and stabilizes microtubules, enabling transport of cellular cargo along neurons in the central nervous system ([@bb0465]). Through microtubule regulation, tau mediates neuronal signaling and synaptic plasticity ([@bb0100]). Tau has also been observed to modulate DNA conformation and expression by both direct and indirect mechanisms, contributing to the regulation of genomic stability ([@bb0690]; [@bb0610]). Microtubule binding is dynamically switched on/off by dephosphorylation/phosphorylation during the cell cycle; Tau must unbind for mitosis to occur for example.

There are more than 20 neurodegenerative diseases associated with the pathology of tau ([@bb1625]). In AD, pathologic tau manifests as neurofibrillary tangles (NFTs) in the brain. In healthy, terminally differentiated, post-mitotic cells such as neurons, cytosolic tau is phosphorylated at about 2 sites on average, while in NFTs, tau is hyperphosphorylated ([@bb0590]), at about 7--8 sites on average ([@bb0630]; [@bb0945]). Phosphorylated tau can sequester normal tau and disrupt microtubule assembly ([@bb0035]), leading to neurodegeneration. Multiple (≈80) serine, threonine, and tyrosine sites on tau are engaged to varying degrees when tau is hyperphosphorylated ([@bb0100]; [@bb1065]).

Tau protein is secreted from neurons; in AD it can propagate to nearby neurons along synaptic circuitry ([@bb0410]; [@bb0480]; [@bb0905]; [@bb0710]; [@bb0900]). Tau tangles then proliferate from the entorhinal cortex to the hippocampus and cortex as the disease progresses ([@bb0215]). Tau oligomers are highly diffusive (mobile), and are toxic to neurons ([@bb0505]; [@bb1460]). After prolonged incubation, human brain-derived tau oligomers can propagate the spread of abnormal tau conformation of endogenous murine tau, i.e. tau oligomers may exhibit inter-species templating of misfolding ([@bb0880]) reminiscent of prion-like behavior ([@bb0260]). There is much accumulating evidence that pathologic tau species from mouse or human tissue exhibits prion-like properties of propagation and inter-cellular infection ([@bb0305]; [@bb0905]; [@bb0310]; [@bb1275]; [@bb0680]; [@bb0675]; [@bb0315]; [@bb0605]; [@bb1020]; [@bb0510]; [@bb0475]).

[@bb0745] have shown that immunodepleting brain lysates from P301S transgenic mice with phospho-specific antibodies abolishes prion-like tau seeding activity in HEK cell cultures and transgenic P301S mice. Only oligomers containing more than about 10 tau molecules were seed-competant. Thus, tau hyperphosphorylation may inadvertently contribute to a conformational reorganization inducing large tau oligomers to become prion-like. The relative abundance in human brain of prion-like, phosphorylated tau, rather than the total amount of inert, insoluble tau, appears to decrease with AD patient longevity ([@bb0095]).

In AD, increased *β*-amyloid precedes the onset of symptoms and clinical disease by roughly 15 years. Years after A*β* pathology is present, tau biomarker abnormalities are detectable, and their accumulation correlates more closely with the severity of dementia than does amyloid deposits ([@bb0110]; [@bb0170]; [@bb1030]; [@bb1340]; [@bb1035]), as observed for example by serial PET scans of amyloid and tau, and comparing with cognition ([@bb0635]). Alzheimer\'s disease appears to manifest as an A*β*-exacerbated tauopathy.

[@bb1250] found that in transgenic mice overexpressing human A*β*, reducing endogenous tau levels could prevent AD-like behavioral decline. High A*β* level was unaffected. Reducing tau could also protect neurons from excitotoxic dysfunction. Similar findings have been observed by administration of tau antibody 43D in triple transgenic (3 × Tg) mice, where the antibody reduced total tau and hyperphosphorylated tau, decreased APP production and thus A*β* production, and increased microglial activation and complement C1q and C9 levels ([@bb0400]). These latter effects resulted in less A*β* plaque load. In another study using a phospho-specific C-terminal tau antibody, in addition to the expected decreases in soluble and insoluble tau, A*β* deposits were decreased by ≈84% ([@bb1210]). Taken together, the above evidence suggests that reducing tau levels via passive or active immunotherapies could thus represent an effective strategy for treating AD and related tauopathies. A concern in pursing such an approach however is to avoid targeting functional tau. An antibody selective to pathological tau is most desirable as a safe and effective therapeutic.

Current immunotherapies directed against tau are listed in [Table 2](#t0010){ref-type="table"} , along with their epitopes, immunization strategy, binding selectivity if known, antibody backbone isotype, and current and completed trial information. For antibodies currently in clinical trials directed against tau, [Fig. 5](#f0025){ref-type="fig"} shows the locations of their corresponding epitopes on the tau primary sequence. The order of antibodies below is loosely based on their current stage in clinical trials as well as their historical development.Table 2Antibodies to tau currently in clinical development.Table 2AntibodyEpitope locationImmunization strategyBinding SelectivityAb species and backbone isotypeCurrent Status (2019--2020)CompanyClinical outcomesLast completed Trial (Disease,Phase)Patient stageReduced tau burdenGosuranemab, BIIB092, BMS-986168, IPN007/IPN002)15--24In vitro aggregated full-length tauM, NFT?, eTau[a](#tf0020){ref-type="table-fn"}humanized IgG4[NCT03352557](NCT03352557){#ir0235} (AD,II)iPerian/Bristol-Meyers Squibb/Biogen[NCT02460094](NCT02460094){#ir0240} (PSP,I), [NCT03068468](NCT03068468){#ir0245} (PSP,II,d[d](#tf0035){ref-type="table-fn"})MCI/Mild AD+ABBV-8E12 (C2N-8E12, HJ8.5)25--30 (within 22--34)recombinant full-length tauM, NFT, eTauhumanized IgG4[NCT03712787](NCT03712787){#ir0250} (AD,II), [NCT02880956](NCT02880956){#ir0255}(AD,II)C2N Diagnostics/Abbvie[NCT02494024](NCT02494024){#ir0260} (PSP,I) [NCT03391765](NCT03391765){#ir0265} (PSP,I,d)Early AD+Zagotenemab (LY3303560, MC-1 IgG1)7--9/312--322 (discontiguous)Immunopurified PHFsM-,O,NFThumanized IgG4[NCT03518073](NCT03518073){#ir0270} (AD,II)Eli Lilly[NCT02754830](NCT02754830){#ir0275}, [NCT03019536](NCT03019536){#ir0280} (AD,I)healthy, mild to moderate AD--[c](#tf0030){ref-type="table-fn"}Semorinemab (RO7105705, MTAU9937A, RG6100)2--24 (C-terminal portion)recombinant oligomersM,NFT,eTauhumanized IgG4[NCT03828747](NCT03828747){#ir0285} (AD,II), [NCT03289143](NCT03289143){#ir0290} (AD,II)AC Immune, Genentech, Hoffmann-La Roche[NCT02820896](NCT02820896){#ir0295} (AD,I)Mild to moderate AD+BIIB076 (NI-105.6C5 huIgG1*λ*)probably 125−131N/A: B-cells from healthy subjectsM, PFF, NFThuman IgG1[NCT03056729](NCT03056729){#ir0300} (AD,I)Biogen/Neurimmune[NCT03056729](NCT03056729){#ir0305} (AD,I)Healthy/MCI AD+[b](#tf0025){ref-type="table-fn"}RG7345 (RO6926496)416--430 (pS422)416--430 (pS422) peptidephospho M, PHFhumanized IgG1 or IgG4[NCT02281786](NCT02281786){#ir0310} (I,d)Hoffmann-La Roche[NCT02281786](NCT02281786){#ir0315} (I,d)healthy males−UCB0107 (D IgG4)235--246Recombinant tau fibrilsM,O,PHFhumanized IgG4 or IgG1[NCT03464227](NCT03464227){#ir0320} (AD,I), [NCT03605082](NCT03605082){#ir0325} (AD,I) [NCT04185415](NCT04185415){#ir0330} (PSP,I,s)UCB Biopharma[NCT03464227](NCT03464227){#ir0335} (I), [NCT03605082](NCT03605082){#ir0340} (I)Healthy males, healthy m/f−JNJ-63733657 (B296, PT3)204--225 (pT212/pT217)PHF from AD patientsM,PHF (ptau)humanized, likely IgG1[NCT03375697](NCT03375697){#ir0345} (prodromal, mild AD,I)Janssen[NCT03689153](NCT03689153){#ir0350} (I)healthy m/f+NPT088\--[c](#tf0030){ref-type="table-fn"}N/A: Human IgG -viral g3p GAIM chimeraO,F/PHuman IgG1[NCT03008161](NCT03008161){#ir0355} (I)Proclara Biosciences[NCT03008161](NCT03008161){#ir0360} (I)Mild to moderate AD−[^4][^5][^6][^7]Fig. 5Epitope locations on the primary sequence of tau, for antibodies currently in clinical trials. Black bars indicate epitope locations; Pink bands on epitopes indicate phosphorylated sites and thus selectivity to the phosphorylated species. Domain structural features are shown for the longest isoform of tau (2N4R, 441 aa). The 2N4R isoform contains two N-terminal domains (N1 and N2 of 29 aa each), two proline-rich domains (P1 and P2 of 46 aa each), and four microtubule-binding domains (R1-R4 of 31 aa each). Zagotenemab has a discontiguous epitope. Specific epitope locations are listed in [Table 2](#t0010){ref-type="table"}. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 5

5.1. Gosuranemab (BIIB092) {#s0150}
--------------------------

As described above, extracellular tau is thought to mediate the onset, cell-to-cell propagation, and neurodegenerative progression of AD as well as the other tauopathies, including progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), and some cases of frontotemporal lobar degeneration. BIIB092 was developed to target extracellular tau.

[@bb0220] reprogrammed skin cells from patients with sporadic or presenilin-1-mutant AD to induced pluripotent stem cells (iPSCs), which they then differentiated into cortical neurons. Compared to age-matched control neurons, the AD-derived cells secreted N-terminal fragments of tau (eTau) into the extracellular space. Electrophysiological analysis showed that the secreted eTau induced neuronal hyperactivity, which could itself increase A*β* production in a kind of toxic *pas de deux* ([@bb0730]; [@bb0400]).

Bright et al.\'s immunization strategy was to raise a mouse monoclonal antibody by standard immunization using in vitro aggregated full-length (2N4R) tau, rather than selectively presenting a particular epitope. The purified antibodies were then screened and selected afterward for high binding affinity to both the secreted eTau and full-length tau, as well as their ability to ameliorate eTau-induced neuronal hyperactivity.

BIIB092, the humanized version of the above mouse monoclonal antibody (IPN002), is an IgG4 monoclonal that recognizes a linear, non-phosphorylated epitope in the N-terminal region of tau consisting of amino acid residues ^15^AGTYGLGDRK^24^ ([@bb0580]; [@bb1205]).

In phase 1 trials, BIIB092 was found to be safe and well-tolerated; there were no severe adverse effects in the low and moderate dose arms, and 8% (2/24) severe adverse effects in the highest dosage arm. These were not considered to be related to the drug, and they all eventually resolved. The antibody reduced unbound N-terminal tau in CSF: A reduction of 91--97% was sustained by day 85 across all doses ([@bb0210]). However, AD biomarkers such as total tau and ptau181 ([@bb0395]; [@bb1455]; [@bb1685]) were not reduced by BIIB092, perhaps either due to N-terminal truncation of these constructs, or the presence of antibody-bound fragments in the CSF. Such observations have motivated some of the tau mid-region binding antibodies discussed below. Two phase II clinical trials were initiated in 2017 for AD and PSP (see [Table 2](#t0010){ref-type="table"}). The PSP trial (PASSPORT, [NCT03068468](NCT03068468){#ir0540}) was discontinued in December 2019, for failure to meet or either primary or secondary endpoints ([@bb0080]). The AD trial (TANGO trial, [NCT03352557](NCT03352557){#ir0550}) is currently ongoing, and has a completion date of 2024.

5.2. ABBV-8E12 {#s0155}
--------------

The mouse monoclonal IgG2b antibody HJ8.5 has been raised by conventional immunization using recombinant full-length human tau. The state of tau (monomeric, aggregated) as well as the adjuvant immunogen has to our knowledge not been disclosed ([@bb0685]). The antibody is selective to human tau and does not bind to mouse tau. The epitope has been published as either ^25^DQGGYT^30^ ([@bb1670]) or ^22^DRKDQGGYTMHQD^34^ ([@bb0685]). Indeed the epitopes align by BLAST primarily to one of the few gap regions in the mouse-human sequence alignment: ^22^DRKDQGGYTMHQD^34^ aligns to - - - - - - - - ^19^TLLQD^23^ in mouse, and ^25^DQGGYT^30^ aligns to - - - - - T^19^ in mouse. (i.e. human ^30^TMHQD^34^ aligns with mouse ^19^TLLQD^23^ above). The antibody binds both tau monomer and stains neurofibrillary tangles ([@bb1670]), and does not appear to be conformationally selective to oligomeric or other species.

The antibody was selected for development based on its ability to block uptake and inhibit seeded tau aggregation in in vitro assays, where neuronal cells were exposed to tau-P301S mouse brain lysates containing tau aggregates ([@bb1670]). Like BIIB092, it is thus screened for the ability to target extracellular tau. In human P301S tau-transgenic mice, administration of HJ8.5 reduced brain neurofibrillary pathology and phospho-tau abundance, and reduced atrophy of hippocampal brain volume ([@bb1675]).

ABBV-8E12 (C2N-8E12) is the humanized IgG4 antibody version of HJ8.5. It was found safe and tolerable as IV injections in phase I trials ([NCT02494024](NCT02494024){#ir0555}, [@bb1615]). Phase 2 trials for PSP were discontinued in July 2019 however, after futility analysis. Several press releases corroborate this (e.g. [@bb0075]), although at present no trials are listed as halted or discontinued for 8E12 on [clinicaltrials.gov](http://clinicaltrials.gov){#ir0565}. ABBV-8E12 is also in a phase 2 trial for early AD, which is continuing without changes. One rationale for continuing is that the stage of tauopathy of patients in the AD trial may be relatively early compared to those in the PSP trial. The current phase 2 trials for PSP and AD using BIIB092, which also targets an N-terminal epitope, are also continuing as originally planned.

5.3. Zagotenemab (LY3303560) {#s0160}
----------------------------

The antibody Alz-50, developed now over 34 years ago ([@bb1650]), selectively recognizes paired helical filaments (PHFs) of tau in AD brains. Alz-50 was used to purify PHFs from AD brain homogenates by immunoaffinity, and these purified PHFs were then used as immunogens in mice to raise the monoclonal IgG1 antibody MC-1 ([@bb1545]; [@bb0775]). Perhaps surprisingly, these two antibodies share a similar discontiguous epitope on tau. Alz-50 also recognizes the transcriptional repressor protein FAC1 (an off-pathway target), while MC-1 does not. The discontiguous epitope requires N-terminal amino acids 7--9, and amino acids 313--322 in the third microtubule binding domain ([@bb0775]). Removing either component of the epitope ablates binding. As well, mixing chains containing only the N-terminal component with chains containing only the C-terminal component also showed no reactivity to the antibody ([@bb0775]), so it appears that both components of the epitope must be present on the same chain.

The discontiguous epitope is present in an aberrant conformation of tau that is present in a nonfilamentous, soluble form of tau indistinguishable from NFTs by ELISA and immunoblotting, and is also present in PHFs ([@bb1595]). Reactivity to the antibody appears to correlate with the severity and progression of AD ([@bb1550]). Passive immunization experiments using intra-peritoneal injections have shown that MC-1 could reduce tau pathology in the forebrain of transgenic P301L tau mice. ([@bb0285]; [@bb0390]).

LY3303560 (zagotenemab) is the humanized version of MC-1. It is likely an IgG4 isotype, with mutations in the constant region to reduce effector function and prevent subunit exchange ([@bb0050]). The antibody recognizes a conformational epitope of tau with primary epitope located in the N-terminal region ([@bb0025]), but which is also discontiguous like MC-1, and involves amino acids ^7^EFE^9^ and ^312^PVDLSKVTSKC^322^ ([@bb0050]). One possible issue in this regard is the potential loss of reactivity to N-terminally truncated species. LY3303560 is selective for tau aggregates over monomer ([@bb0025]): The affinity to soluble tau aggregates (*K* ~*D*~ \< 220pM) is driven by avidity, and is much higher than the affinity for monomer (*K* ~*D*~ ≈ 235nM).

Two phase 1 trials for zagotenemab have completed, one for healthy volunteers or mild to moderate AD volunteers ([NCT02754830](NCT02754830){#ir0570}) and another for mild to moderate AD volunteers ([NCT03019536](NCT03019536){#ir0575}) ([clinicaltrials.gov](http://clinicaltrials.gov){#ir0580}). Results have not yet been reported. A phase 2 trial is currently active for patients with early AD ([NCT03518073](NCT03518073){#ir0585}), scheduled to complete in October 2021.

5.4. Semorinemab (RO7105705) {#s0165}
----------------------------

The development of semorinemab (RO7105705) seeks to minimize Fc*γ* receptor activation, and seeks to maximize binding across different extracellular tau species. The argument for a pan-tau antibody is that nearly all antibody-accessible tau is extracellular, and that any extracellular tau could drive pathology and so is a viable target for elimination.

"Effectorless" antibodies may be engineered by making D265A and N297G (DANG) mutations in the Fc region of the antibody, which when combined, abolish binding to microglial Fc*γ* receptors. ([@bb0350]). Preclinical studies have shown that effectorless antibodies protected neurons from toxicity better than the unmodified version did, and that effectorless antibodies can remove aggregates in mouse models as well as normal antibodies ([@bb0885]). Similarly, RO7105705 is a humanized IgG4, which only weakly activates microglial Fc*γ* receptors, minimizing inflammation. It should be noted that strict adherence to IgG4 antibodies to minimize effector response is not universally embraced. It is argued for example that the benign safety profile of the active immunotherapy AADvac-1, which induces predominantly an IgG1 antibody response, implies that at least pathological tau can be safely targeted with IgG1 antibodies ([@bb1060], [@bb1065]).

Antibody generation for RO7105705 likely proceeded by vaccination of mice with recombinant, phosphorylated, and oligomerized human tau ([@bb0020]). Antibody selection then proceeded by assaying for binding to full-length tau, then to phosphorylated tau and oligomerized tau, with the aim to find antibodies that bound equally well to both tau and post-translationally modified tau. Binding to all 6 isoforms of human tau was also used as a selection criterion. To maintain pan-tau properties, epitopes that mapped to regions with a high density of phosphorylated residues (S,T,Y) were avoided. The epitope of RO7105705 is likely within residues 2--24 (^2^AEPRQEFEVMEDHAGTYGLGDRK^24^, [@bb0020]). The antibody reacts with all 6 isoforms of human and primate tau, but not mouse tau (residues ^19^GLGDRK^24^ are absent in mouse tau), implying that the epitope resides in the C-terminal portion of the above sequence.

RO7105705 was found to protect neurons from tau-mediated toxicity in cell-based studies. In transgenic mice expressing human mutant P301L tau, 13 weeks of treatment with either 3, 10, or 30 mg/kg of RO7105705 reduced pathological tau in the brain in a dose-dependent fashion; The antibody also raised tau levels in blood plasma, implying target engagement and stabilization in the periphery, akin to the peripheral sink mechanism proposed for A*β* antibodies such as solanezumab and ponezumab. Chronic dosing was safe in both mice and cynomolgus monkeys ([@bb0130]).

Phase 1 studies have shown that the antibody is safe and tolerable in healthy volunteers, even at extraordinarily high single doses of 16,800 mg ([@bb0835]). Two current phase II trials, one for prodromal/probable AD participants (TAURIEL trial, [NCT03289143](NCT03289143){#ir0590}), and one for moderate AD participants ([NCT03828747](NCT03828747){#ir0595}) are ongoing.

5.5. BIIB076 {#s0170}
------------

Healthy human subjects who are at risk for AD, either because of advanced age or genetic predisposition, yet who exhibit no AD symptoms or unusually slow progression, provide a valuable therapeutic resource for the isolation of antibodies to AD-related proteins. This strategy has been also exploited in the development of aducanumab, as mentioned above in Section 4.7. Tau disease-selective monoclonal antibodies isolated from memory B cells in such healthy subjects with no signs of a neurodegenerative tauopathy are expected to have excellent safety profile and lack of immunogenicity, and to be already evolutionarily optimized and affinity matured by the human immune system. This therapeutic strategy has motivated the development of 3 lead antibodies in the patent literature, NI-105.4E4, NI-105.4A3, and NI-105.24B2 ([@bb0290]; [@bb1055]).

BIIB076 is cited as being derived from NI-105.6C5 ([@bb0055]), another antibody in the patent literature ([@bb1605]) developed similarly by Neurimmune\'s reverse translational approach, which mines antibody sequences isolated from healthy human B cells. The epitope of NI-105.6C5 is ^125^ARMVSKS^131^ ([@bb0360]; [@bb1605]), which is between N-terminal domain N2 and proline-rich domain P1.

BIIB076 is a fully human IgG1, which binds with subnanomolar affinity to both human and cynomolgus monkey recombinant tau. ([@bb0385]). It is a "pan-tau" antibody, recognizing monomeric and fibrillar forms, as well as tau isolated from healthy human and Alzheimer\'s disease brains. No cell-based or mouse preclinical work with this antibody has been published. BIIB076 exhibited no adverse toxicology or pathology in cynomolgus monkeys, and CSF total and free tau levels were significantly reduced in the highest BIIB076 dose animals in this study ([@bb0385]). These results established a positive safety profile for inclusion of BIIB076 into phase I trials. This trial ([NCT03056729](NCT03056729){#ir0610}) recruited healthy and mild-AD volunteers to monitor adverse events and pharmacokinetics ([Table 2](#t0010){ref-type="table"}). The trial protocol was modified in June 2019, to drop the more advanced AD cohort and adopt adverse events as the sole primary outcome. The trial has recently finished in March 2020.

5.6. RG7345 (RO6926496) {#s0175}
-----------------------

Phosphorylation at S422 is a part of the maturation process of PHFs, and generally precedes proteolytic cleavage at least at some locations such as D421 ([@bb0600]). pS422 is prominent in early stages of Alzheimer\'s disease and persists until late-stages, making it an attractive target. Active immunizations also support pS422 as a viable target. In a transgenic mouse model overexpressing a mutant, alternative isoform of tau (the 412 amino acid isoform missing N-terminal domain N2, with mutations G272V and P301S, under a neuron-specific promotor (Thy1.2)), active immunization with a peptide containing pS422 decreased insoluble tau in the brain, and this decrease correlated with significant memory improvement using the Y-maze spatial memory task ([@bb1485]).

Polyclonal antibodies to epitopes containing phospho-serine 422, which resides near the C-terminus of tau, have been shown to be reactive to brain extracts from patients with AD, PSP, corticobasal degeneration (CBD), and other neurodegenerative diseases, while such polyclonal antibodies are unreactive to controls ([@bb0235]). pS422 has thus been identified as a pathological epitope found in several diseases with neurofibrillary degeneration. Polyclonal pS422 antibodies recognized intra-neuronal NFTs in cells that had lost their integrity; extra-neuronal NFTs were also recognized. In contrast to some other phospho-selective antibodies with epitopes at sites pT153, pS262, and T231, staining of pre-tangles with pS422 was rare ([@bb0120]).

RG7345 was developed from mice and/or rabbits immunized with phospho-peptide ^416^SIDMVD(*pS*)PQLATLAD^430^ coupled to KLH, where antibodies were subsequently screened for selective binding to the peptide with pS422 ([@bb0195]). The antibody was then recombinantly expressed with a murine IgG1 or a human IgG1 isotype. The isotype of the humanized antibody has not been disclosed to our knowledge, and patent protection specifies both IgG1 and IgG4 isotypes ([@bb0490]). In triple transgenic mice expressing mutant APP, PSEN2, and MAPT (TauPS2APP mice), the murine IgG1 was able to significantly reduce tau pathology compared to vehicle-treated controls, if intraperitoneal treatment persisted for 4 months ([@bb0335]). In this same study, [@bb0335] observed that antibodies were incorporated into neurons via endocytosis of bound antibody-antigen complex. This finding offers a possible explanation as to how anti-tau antibodies might be effective in treating intra-neuronal tau pathology, but also indicates that extracellular tau may not be exclusively targeted.

The antibody RG7345 has been advanced to phase I clinical trials ([NCT02281786](NCT02281786){#ir0615}), which were completed in October 2015. Development of RG7345 has been discontinued by Roche however; No reasons have yet been reported.

5.7. UCB0107 {#s0180}
------------

There is some evidence that antibodies binding to the mid-region of tau are more effective at blocking cell-to-cell propagation than those targeting the N-terminus, though this notion is still speculative, as some N-terminal binding antibodies such as BIIB092 and ABBV-8E12 were selected for blocking cell-to-cell transmission of pathology, and findings for these antibodies as well as RO7105705 indicate at least partial efficacy of N-terminal antibodies in blocking the spread of pathogenic tau.

[@bb0355] employed a high-throughput screening approach wherein they immunized rabbits with 17 different peptide constructs targeting various regions of tau, and they immunized rats with either recombinant tau fibrils or human AD brain-derived PHF tau. This resulted in 94 ELISA-reactive monoclonal antibodies, which were then screened by surface plasmon resonance (SPR) for binding to tau monomer and AD-PHFs. 51 of these antibodies were then screened for the ability to block cell-to-cell propagation of tau aggregation in HEK293 cells seeded with AD PHF. Five antibodies displayed robust and complete neutralization of pathological tau seeds.

The most potent of these 5 antibodies (antibody D) came from a rat immunization with recombinant tau fibrils. An equimolar mix of four tau isoforms (2N4R, 1N4R, 0N4R and 0N3R, see [Fig. 5](#f0025){ref-type="fig"}) containing both soluble tau and insoluble fibril tau was used for the recombinant tau fibril rat immunization ([@bb0850]). Interestingly, in the cell-based assay testing propagation, recombinant antibodies using CDRs in the existing patent literature for BIIB092, ABBV-8E12, and LY3303560 were significantly less effective than antibody D in blocking seeded tau aggregation ([@bb0355]). One explanation is that these antibodies target the N-terminal region of tau as that tends to be where affinity is highest, however N-terminal tails are thought to be exposed outside the core of tau fibrils where they may be cleaved by proteases ([@bb0355]). Thus at least some proteopathic tau seeds may be missing N-termini.

In P301L human tau transgenic mice given hippocampal injections with AD brain homogenate or PHF from AD brains, intraperitoneal administration with high doses (30 mg/kg) of antibody D were able to block the progression of tau seeding pathology to distal brain regions ([@bb0030]). This result was recapitulated for a tau fragment injectant containing only the 4 microtubule binding repeats with mutation P301L, which antibody D does not bind given its epitope location. This latter result explicitly demonstrates blockage of seeded endogenous tau.

UCB0107 is the humanized version of antibody D. Its specific isotype is likely an IgG4 ([@bb0060]; [@bb0850]). The developers are fairly agnostic as to whether at least some effector function is desirable or if it is to be avoided. The epitope of UCB0107 has been mapped to residues ^234^SPSSAKSRLQTA^246^, which is at the end of tau\'s second proline-rich region and just before its first microtubule-binding domain. The (undeposited) co-crystal structure contains a bound tau peptide with residues 234--244, at least part of which is in a helical structure ([@bb0850]).

Two phase I clinical trials for UCB0107 ([NCT03464227](NCT03464227){#ir0625} and [NCT03605082](NCT03605082){#ir0630}) were completed in December 2018 and March 2019 respectively, but results have not yet been reported. A phase I trial for PSP initiated in December 2019 ([NCT04185415](NCT04185415){#ir0635}) has been halted as a precautionary measure due to the COVID-19 pandemic.

5.8. JNJ-63733657 {#s0185}
-----------------

Functional tau that is bound to axonal microtubules is hypo-phosphorylated, while aggregated tau in AD is hyper-phosphorylated. This post-translational process along the pathological maturation pathway can provide unique epitopes that are distinct from the physiologically active pool of tau. JNJ-63733657 is a monoclonal antibody likely of IgG1 isotype, with selective affinity for paired helical filament (PHF) tau and tau phosphorylated at select sites described below.

The murine precursor to JNJ-63733657, PT3, was derived from immunization of a Balb/c mouse with enriched PHF-tau (ePHF-tau) from AD brain. The antibody was tested for target selectivity to phospho-tau versus non-phospho-tau by ELISA, western blot, and immunohistochemistry (IHC). The humanized antibody B296 has the same CDR sequences as PT3, and was humanized by pairing variable regions of PT3 with a human IgG1/*κ* constant region ([@bb0980]); This antibody was affinity matured to generate JNJ-63733657. B296 has a strong affinity of 27 pM to PHF tau. B352, an IgG4 variant of B296 with the same variable regions, had an affinity of 43 pM to PHF-tau. Both of these antibodies did not bind unphosphorylated tau.

The antibody binds to a phosphorylated epitope in the proline rich domain P2 of tau protein between residues G204-K225. For high-affinity binding by the murine precursor PT3 (*K* ~*D*~ \< 25nM to the phospho-peptide), either T212 or T217 must be phosphorylated. If both T212 and T217 are phosphorylated, *K* ~*D*~ \< 1nM. Thus the optimal sequence is ^204^GTPGSRSR(*pT*)PSLP(pT)PPTREPKK^225^, although S214 may be phosphorylated as well and *K* ~*D*~ \< 1nM preserved, and binding to sequences with pS214/pT217 or pS210/pT217 have affinity *K* ~*D*~ ≈ 6nM ([@bb0980]). The epitope of PT3 is distinct from other reported epitopes of phospho-dependent anti-tau antibodies, such as AT8, AT180, and anti-tau pS422.

The co-crystal structure of the antibody-epitope has been obtained ([@bb0980]) but not yet deposited on the PDB. Structurally, the bound epitope is extended and linearized when bound to the antibody in the co-crystal structure.

Similarly to the assay described above in Section 5.7, a cell-based assay may be used to measure the inhibition of tau propagation by anti-tau antibodies, when the cells are transfected with a co-incubated mixture of AD brain homogenate and anti-tau antibody. [@bb1520] used HEK cells expressing two chromophore-tagged tau repeat-domain fragments, which will generate a FRET signal if they are in proximity upon aggregation. FRET-positive cells were then sorted and counted after transfection to test the efficacy of a panel of antibodies. Anti-tau antibodies tested in this system vary in their ability to immunodeplete the seeding capacity from human AD brain homogenates ([@bb0205]; [@bb0070]). Similar to the development of UCB0107, antibodies against tau\'s mid-region best removed pathogenic seeds, whereas antibodies to the N-terminal region of tau only weakly suppressed seeding, again likely because of N-terminal cleavage of propagative aggregates by proteases. In contrast to the findings of [@bb0355], Mercken and colleagues saw some efficacy for both BIIB092 and ABBV-8E12 in their cell-based assay ([@bb0070]).

An in vivo P301L tau transgenic mouse model was tested by [@bb0980], wherein intraperitoneal injection of PT3 (or controls) was followed by seeding induction by intracranial injection of AD-brain-derived PHF-tau. In this model, peripheral administration of PT3 was able to significantly reduce the seeded propagation of tau aggregation in mouse brains.

A recent phase I clinical trial in healthy Japanese participants aged 55--75 finished in July 2019 ([NCT03689153](NCT03689153){#ir0650}). JNJ-63733657 was found to be generally safe and well-tolerated. CSF levels were ≈0.2% of serum levels, and a dose-dependent reduction in phospho-S217 tau was observed in the CSF following antibody administration ([@bb0515]). A 2nd phase I trial testing safety and pharmacokinetics in both healthy participants or participants with prodromal or mild Alzheimer\'s disease has recently completed in December 2019. Results have not yet been reported.

5.9. NPT088 and BIIB080 {#s0190}
-----------------------

As mentioned above in the context of A*β* -targeting therapies (Section 4.13), NPT088 is a generic amyloid-binding antibody that is reactive to both A*β* and tau. In transgenic mouse models overexpressing mutant APP that elevates levels of A*β* (Tg2576 mice expressing K670N/M671L APP) Y-maze performance was significantly increased and novel object recognition was significantly improved after weekly intraperitoneal dosing with NPT088 for 10 weeks or 14 weeks respectively ([@bb0895]). Staining of brain sections with a PHF-tau-specific monoclonal antibody (AT8, see below) shows a reduction in PHF in these systemically treated mice compared to controls ([@bb0895]). Since NPT088 is specifically reactive to amyloid fibrils ([Table 1](#t0005){ref-type="table"}), these results suggest that binding to monomeric tau may be unnecessary for efficacy of an immunotherapeutic, and that targeting oligomers and/or fibril species may be sufficient. This notion bears some analogy with the problem of avoiding target distraction due to abundant monomer concentration for A*β* therapeutics. Another potential advantage of a therapeutic such as NPT088 with reactivity to both A*β* and tau is that if a combination therapy is required, NPT088 alone may still be effective clinically.

BIIB080 is an antisense oligonucleotide (ASO) that silences the translation of tau mRNA as described below, so it can be thought of as a passive but not a protein immunotherapeutic. This antisense oligonucleotide targets the beginning of exon 5 (at the 5′ end). In a study investigating 31 candidate morpholinos, the morpholino targeting this specific site (extended by 3 bases to bracket the intron-exon boundary of the splice acceptor site) was one of the most effective in significantly reducing total MAPT transcript levels ([@bb1420]). Exon skipping of exon 5 (as well as 1 and 7) results in changing the open reading frame of the mRNA, leading to a premature stop codon likely resulting in nonsense-mediated decay.

In preclinical studies, the ASOs of BIIB080 had a phosphorothioate backbone to improve nuclease resistance and promote cellular uptake. In human P301S tau-transgenic mice, reduction of tau expression by BIIB080 ASOs resulted in fewer tau inclusions, reversal of preexisting phosphorylated tau and Thioflavin S pathology, reduced rates of neuronal death, and extension of mouse survival time ([@bb0435]). Although the effects of tau knock-down by an anti-sense oligonucleotide may be different in humans than in a mouse model that by design is overexpressing mutant tau, these encouraging initial results have led to an active clinical trial ([NCT03186989](NCT03186989){#ir0655}) for BIIB080.

5.10. Selected preclinical /research tau antibodies {#s0195}
---------------------------------------------------

DC8E8 will bind to any one of 4 separate epitopes on tau having similar sequence motif ([@bb0855]): ~268~HQPGGG~273~ (located within microtubule binding region 1 (MTBR1)), ~299~HVPGGG~304~ (in MTBR2), ~330~HKPGGG~335~ (in MTBR3) or ~362~HVPGGG~367~ (in MTBR4). Several PDB crystal structures of the DC8E8 Fab in the complex with a 14-mer tau peptide have been determined; The antigen-binding region from 5MO3.pdb is shown in [Fig. 6](#f0030){ref-type="fig"} , which contains the epitope ~298~KHVPGGGS~305~. The epitope is mainly linear, with a *β*-turn in the glycine region. The backbone contacts in the glycine region are apparently important for antibody affinity: The above 6-residue epitope motifs compete with tau~151−391~ for binding to antibody DC8E8, but removal of the C-terminal glycine from the epitope eliminates the ability of the corresponding peptide to compete ([@bb0855]).Fig. 6Co-crystal structures of the antigen-binding regions of two preclinical antibodies to tau, bound to their epitopes. Antibodies, Protein Databank entry, and epitopes are: (left) DC8E8, PDB [5MO3](pdb:5MO3){#ir0035}, structured epitope amino acids 298--305; (right) AT8, PDB [5E2W](pdb:5E2W){#ir0040}, structured epitope amino acids 202-209.Fig. 6

Binding of the antibody to this epitope on tau interfered with pathological tau-tau interactions in an in vitro assay, reducing the amount of oligomeric tau by 84% ([@bb0855]). In vivo, DC8E8 significantly reduced the amount of insoluble oligomerised tau and the number of early and mature neurofibrillary tangles in transgenic mouse brains. The humanized version of the murine antibody DC8E8 is AX004. AX004 has been shown to block cell-to-cell propagation of tau by preventing neuronal internalization of extracellular tau, as mediated between the microtubule binding domain containing DC8E8 epitopes, and Heparan Sulfate Proteoglycans (HSPGs) on the neuron surface ([@bb1610]). As mentioned above in Section 2.1.2, the epitope when used as an active vaccine in humans is AADvac-1.

The murine monoclonal IgG1 antibody AT8 ([@bb0975]; [@bb0550]) is a widely used anti-tau antibody to probe phosphorylated PHFs and assess tau phosphorylation at the amino acids Ser 202, Thr 205 and Ser 208. AT8 recognizes an epitope doubly phosphorylated at serine 202 and threonine 205. AT8 is about 10% cross-reactive to the doubly phosphorylated epitopes S199/S202 and T205/S208. The antibody has no cross-reactivity with unphoshorylated tau. The epitope is ^200^PG(*pS*)PG(pT)PG^207^ ([@bb1165]). The co-crystal structure of the antigen-binding fragment of AT8 bound to a triply phosphorylated tau peptide ^194^Ac-RSGYSSPG(*pS*)PG(pT)PG(*pS*)RSR-OH^211^ (residues 202--209 are resolved in the crystal structure) is shown in [Fig. 6](#f0030){ref-type="fig"} ([@bb0935]). Currently AT8 is a useful research antibody; It is unclear if AT8 or a humanized/modified variant will be clinically-relevant.

A tau oligomer-selective monoclonal antibody (TOMA) was developed by Kayed and colleagues ([@bb0275]), by immunizing BALB/c mice with recombinant ("synthetic") tau oligomers. TOMA is a murine IgG1 that selectively recognizes tau oligomers over either monomeric tau or tau NFTs. Its epitope has not been determined/disclosed. In JNPL3 mice, which expresses mutant human P301L tau, a single intracerebroventricular injection of TOMA cleared tau oligomers but did not significantly affect levels of tau monomers or NFTs. The injection also reversed both rotorod locomotor and Y-maze memory deficits---improvements that persisted for 2 months post injection. The binding and clearane of extracellular tau oligomers facilitated by the antibody is thought to lead to efflux of intracellular oligomers, resulting in eventual CNS and serum clearance ([@bb0275]).

The above are just three representative examples of many tau antibodies that are currently in preclinical development. For a more thorough list, the reader is referred to [@bb0755].

6. Summary and discussion {#s0200}
=========================

It is probably too perfunctory to say that current AD therapeutics have had no effect on disease progression. More precisely, AD therapeutics in current clinical trials have generally failed to meet their desired endpoints for the slowing of cognitive decline. It must be noted however that when subgroups of patients from a full cohort have been subsequently analyzed for some therapeutics, cognitive benefits have been observed.

A recurring theme in Alzheimer\'s therapies is the importance of early or even preventative treatment ([@bb0470]; [@bb1415]). Treating other chronic conditions such as atherosclerosis (with statins) or hypertension (with lifestyle modification or anti-hypertensives) as early as possible has generally been advised. There are currently 9 prevention-based clinical trials ongoing since 2018 ([@bb0375]). The occurrence of molecular pathology that appears to undergo prion-like propagation long before any behavioral symptoms manifest may make presymptomatic treatment mandatory for Alzheimer\'s disease. It also may imply that perhaps some of the halted or discontinued therapeutics described above may be effective when used in a preemptive manner.

In line with the above notions of preemptive therapy, solanezumab and gantenerumab have both been tested in a clinical trial (the DIAN-TU trial, [NCT01760005](NCT01760005){#ir0660}) involving subjects with known autosomal-dominant Alzheimer\'s disease mutations, and who are within −15 to +10 years of the predicted or actual age of cognitive symptom onset ([@bb0160]; [clinicaltrials.gov](http://clinicaltrials.gov){#ir0665}). Initial topline results on this trial reported in February 2020 indicated that, disappointingly, the trial had missed a cognitive endpoint consisting of a composite of four cognitive tests developed by the Dominantly Inherited Alzheimer Network. Site investigators agreed that the drugs were likely markedly underdosed, both in dosage amount and duration. Dosage was increased mid-study, but many participants received relatively short durations of the higher dose (roughly 25% of the total duration). Results reported at the April 2020 AAT-AD/PD meeting clarified that the patient cohort was also highly heterogeneous---participants who were symptomatic had descended into moderate dementia before they could be titrated up to a high dose, whereas asymptomatic participants remained stable througout the trial regardless of drug or placebo arm.

In fact, the degree of symptoms appeared to strongly determine how effective the treatment was: Participants who were presymptomatic at baseline improved significantly on logical memory tests and digit symbol substitution tests, and remained stable on MMSE, CDR-SB and functional assessment score (FAS) tests; Participants who were symptomatic did not improve on the logical memory test, and declined on all other tests. These results, though still not conclusive, appear to support the earliest possible intervention.

Additionally, gantenerumab, but not solanezumab, appeared to improve biomarkers. In addition to removing brain amyloid plaques and improving (increasing) the CSF A*β* ~42~/A*β* ~40~ ratio, gantenerumab lowered levels of CSF total tau and phospho-tau181 by ≈1/3, while maintaining the level of CSF neurofilament light. An open-label extension exploring high-dosage gantenerumab for several additional years is currently planned.

Combination therapies are now common in cancer therapeutic treatment ([@bb0995]; [@bb0705]; [@bb1655]; [@bb1280]). Combination therapies may be particularly effective in later stages of AD when multiple biochemical pathways have been altered. Even early stages of AD pathology likely involve multiple proteins and druggable pathways, including both A*β* and tau. Significant mixed pathology is present in up to 70% of dementia cases, further supporting the idea that combination therapies may be most effective and perhaps even necessary. As mentioned in the above section on fibril and oligomer polymorphism, the presence of multiple conformational strains of misfolded protein will limit the efficacy of a single antibody to block propagation and spread of all distinct conformational strains. Concerning challenges for such a combinatoric approach are the timelines required for regulatory approval for separate individual therapeutics, and the disconcerting possibility that if combination therapy is required for benefit, individual drugs will fail to meet primary end points, and support for further development will be difficult to obtain.

By achieving a more thorough understanding of the underlying biochemical mechanisms of Alzheimer\'s disease, we have been able to develop precision therapeutics that target key processes in the molecular pathology, including the prion-like propagative aspects that are central to the spread of the disease. With each trial, we have gained new insights and learned often painful lessons about the insidious nature of this disease. It is up to us to continue to innovate novel solutions to target and stop the spread of AD pathology, and discover the truly effective therapies that natural biology and rational design will someday provide.
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See [www.alzforum.org](http://www.alzforum.org){#ir0375}, 2020c; Includes missense, insertion/deletion, intronic splice-altering, and distinct nucleic but synomymous amino acid mutations.

[^1]: With mutations to reduce effector function.

[^2]: M,O,F/P = Monomers, Oligomers, fibrils/plaques respectively. Here we assume if the antibody binds fibril, it binds plaque. This is generally the case when experimental measurements exist.

[^3]: For the mild AD subgroup of 2 pooled studies.

[^4]: M = Monomers, O=Oligomers, NFT = Neurofibrillary tangles, eTau = extracellular tau, PFF = pre-formed fibrils, PHF = paired-helical filaments.

[^5]: in cynomolgus monkeys.

[^6]: indicates "not reported".

[^7]: d = Discontinued.
